


**Consolidated Financial Statements
and Independent Auditor's Report**

For the year ended 31 March, 2018



Daiichi-Sankyo

Daiichi Sankyo Company, Limited

Contents

	Page
1) Consolidated Statement of Financial Position	1
2) Consolidated Statement of Profit or Loss	3
3) Consolidated Statement of Comprehensive Income	4
4) Consolidated Statement of Changes in Equity	5
5) Consolidated Statement of Cash Flows	7
Notes to the Consolidated Financial Statements	
1. Reporting Entity	8
2. Basis of Preparation	8
3. Significant Accounting Policies	9
4. Significant Accounting Judgments, Estimates and Assumptions	16
5. Standards and Interpretations Issued but Not Yet Adopted	17
6. Operating Segment Information	18
7. Business Combination	19
8. Cash and Cash Equivalents	19
9. Trade and Other Receivables	19
10. Other Financial Assets	20
11. Inventories	21
12. Assets Held for Sale and Liabilities Directly Associated with Assets Held for Sale	22
13. Property, Plant and Equipment	23
14. Goodwill and Intangible Assets	26
15. Investments Accounted for Using the Equity Method	29
16. Income Taxes	30
17. Trade and Other Payables	34
18. Bonds and Borrowings, and Other Financial Liabilities	34
19. Provisions	36
20. Employee Benefits	38
21. Government Grants	42
22. Capital and Other Components of Equity	42
23. Dividends	43
24. Revenue	44
25. Major Expenses by Nature	44
26. Financial Income and Financial Expenses	45
27. Earnings Per Share	46
28. Share-based Payments	47
29. Financial Instruments	51
30. Lease Transactions	57
31. Other Comprehensive Income	58
32. Changes in Liabilities Arising from Financing Activities	58
33. Related Parties	58
34. Commitments	59
35. Contingent Liabilities	59
36. Major Consolidated Subsidiaries and Affiliates	60
37. Subsequent Events	61

Consolidated Financial Statements

1) Consolidated Statement of Financial Position

(Millions of Yen)

	Note	As of March 31, 2017	As of March 31, 2018
ASSETS			
Current assets			
Cash and cash equivalents	8	246,050	357,702
Trade and other receivables	9	231,867	231,529
Other financial assets	10	552,896	429,380
Inventories	11	153,138	172,586
Other current assets		10,461	10,347
Subtotal		1,194,414	1,201,545
Assets held for sale	12	3,374	-
Total current assets		1,197,788	1,201,545
Non-current assets			
Property, plant and equipment	6,13	217,772	217,946
Goodwill	6,14	78,446	75,479
Intangible assets	6,14	217,044	173,537
Investments accounted for using the equity method	15	1,424	1,693
Other financial assets	10	140,856	179,177
Deferred tax assets	16	53,502	40,339
Other non-current assets		8,143	8,035
Total non-current assets		717,190	696,209
Total assets		1,914,979	1,897,754

(Millions of Yen)

	Note	As of March 31, 2017	As of March 31, 2018
LIABILITIES AND EQUITY			
Current liabilities			
Trade and other payables	17,21	219,759	226,164
Bonds and borrowings	18,29	-	20,000
Other financial liabilities	18	535	516
Income taxes payable		57,955	64,609
Provisions	19	41,223	34,015
Other current liabilities		6,285	7,800
Subtotal		325,758	353,105
Liabilities directly associated with assets held for sale	12	1,058	-
Total current liabilities		326,817	353,105
Non-current liabilities			
Bonds and borrowings	18,29	280,543	260,564
Other financial liabilities	18	9,069	8,155
Post-employment benefit liabilities	20	11,381	10,547
Provisions	19	16,350	48,752
Deferred tax liabilities	16	32,294	18,676
Other non-current liabilities	21	67,093	64,911
Total non-current liabilities		416,733	411,608
Total liabilities		743,550	764,713
Equity			
Equity attributable to owners of the Company			
Share capital	22	50,000	50,000
Capital surplus	22	103,750	94,633
Treasury shares	22	(113,952)	(163,531)
Other components of equity	22	124,489	120,504
Retained earnings		1,011,610	1,031,376
Total equity attributable to owners of the Company		1,175,897	1,132,982
Non-controlling interests			
Non-controlling interests		(4,469)	58
Total equity		1,171,428	1,133,041
Total liabilities and equity		1,914,979	1,897,754

2) Consolidated Statement of Profit or Loss

(Millions of Yen)

	Note	Year ended March 31, 2017	Year ended March 31, 2018
Revenue	6,24	955,124	960,195
Cost of sales	25	349,373	346,021
Gross profit		605,751	614,173
Selling, general and administrative expenses	25	302,475	301,845
Research and development expenses	25	214,347	236,046
Operating profit		88,929	76,282
Financial income	26	6,406	8,642
Financial expenses	26	7,710	4,223
Share of profit of investments accounted for using the equity method	15	162	320
Profit before tax		87,788	81,021
Income taxes	16	40,309	21,210
Profit for the year		47,479	59,811
Profit attributable to:			
Owners of the Company		53,466	60,282
Non-controlling interests		(5,987)	(471)
Profit for the year		47,479	59,811
Earnings per share	27		
Basic earnings per share (Yen)		79.63	91.31
Diluted earnings per share (Yen)		79.44	91.10

3) Consolidated Statement of Comprehensive Income

(Millions of Yen)

	Note	Year ended March 31, 2017	Year ended March 31, 2018
Profit for the year		47,479	59,811
Other comprehensive income			
Items that will not be reclassified to profit or loss			
Financial assets measured at fair value through other comprehensive income	16	(9,366)	10,688
Remeasurements of defined benefit plans	16	1,840	1,616
Items that are or may be reclassified subsequently to profit or loss			
Exchange differences on translation of foreign operations	16,31	(7,626)	(10,229)
Share of other comprehensive income of investments accounted for using the equity method	16,31	6	3
Other comprehensive income (loss) for the year		(15,146)	2,078
Total comprehensive income for the year		32,332	61,890
Total comprehensive income attributable to:			
Owners of the Company		38,309	62,361
Non-controlling interests		(5,976)	(471)
Total comprehensive income for the year		32,332	61,890

4) Consolidated Statement of Changes in Equity

Year ended March 31, 2017

(Millions of yen)

	Equity attributable to owners of the Company					
	Share capital	Capital surplus	Treasury shares	Subscription rights to shares	Other components of equity	
					Exchange differences on translation of foreign operations	Financial assets measured at fair value through other comprehensive income
Balance as of April 1, 2016	50,000	103,927	(64,155)	1,935	75,195	69,586
Profit for the year	-	-	-	-	-	-
Other comprehensive income (loss) for the year	-	-	-	-	(7,626)	(9,366)
Total comprehensive income (loss) for the year	-	-	-	-	(7,626)	(9,366)
Purchase of treasury shares	-	(69)	(50,026)	-	-	-
Cancellation of treasury shares	-	-	230	(133)	-	-
Share-based payments	-	-	-	264	-	-
Dividends	-	-	-	-	-	-
Acquisition of non-controlling interests	-	(107)	-	-	-	-
Transfer from other components of equity to retained earnings	-	-	-	-	-	(5,366)
Others	-	-	-	-	-	-
Total transactions with owners of the Company	-	(177)	(49,796)	131	-	(5,366)
Balance as of March 31, 2017	50,000	103,750	(113,952)	2,067	67,568	54,853

(Millions of yen)

	Equity attributable to owners of the Company					
	Other components of equity		Retained earnings	Total equity attributable to owners of the Company	Non-controlling interests	Total equity
	Remeasurements of defined benefit plans	Total other components of equity				
Balance as of April 1, 2016	-	146,717	994,916	1,231,406	2,115	1,233,521
Profit for the year	-	-	53,466	53,466	(5,987)	47,479
Other comprehensive income (loss) for the year	1,835	(15,157)	-	(15,157)	10	(15,146)
Total comprehensive income (loss) for the year	1,835	(15,157)	53,466	38,309	(5,976)	32,332
Purchase of treasury shares	-	-	-	(50,095)	-	(50,095)
Cancellation of treasury shares	-	(133)	(95)	1	-	1
Share-based payments	-	264	-	264	-	264
Dividends	-	-	(43,879)	(43,879)	-	(43,879)
Acquisition of non-controlling interests	-	-	-	(107)	(600)	(708)
Transfer from other components of equity to retained earnings	(1,835)	(7,202)	7,202	-	-	-
Others	-	-	-	-	(7)	(7)
Total transactions with owners of the Company	(1,835)	(7,071)	(36,772)	(93,817)	(608)	(94,425)
Balance as of March 31, 2017	-	124,489	1,011,610	1,175,897	(4,469)	1,171,428

Year ended March 31, 2018

(Millions of yen)

	Equity attributable to owners of the Company					
	Share capital	Capital surplus	Treasury shares	Other components of equity		
				Subscription rights to shares	Exchange differences on translation of foreign operations	Financial assets measured at fair value through other comprehensive income
Balance as of April 1, 2017	50,000	103,750	(113,952)	2,067	67,568	54,853
Profit for the year	-	-	-	-	-	-
Other comprehensive income (loss) for the year	-	-	-	-	(10,229)	10,688
Total comprehensive income (loss) for the year	-	-	-	-	(10,229)	10,688
Purchase of treasury shares	-	(51)	(50,033)	-	-	-
Cancellation of treasury shares	-	-	453	(74)	-	-
Dividends	-	-	-	-	-	-
Acquisition of non-controlling interests	-	(9,064)	-	-	-	-
Transfer from other components of equity to retained earnings	-	-	-	-	-	(4,369)
Others	-	-	-	-	-	-
Total transactions with owners of the Company	-	(9,116)	(49,579)	(74)	-	(4,369)
Balance as of March 31, 2018	50,000	94,633	(163,531)	1,993	57,339	61,171

(Millions of yen)

	Equity attributable to owners of the Company					
	Other components of equity		Retained earnings	Total equity attributable to owners of the Company	Non-controlling interests	Total equity
	Remeasurements of defined benefit plans	Total other components of equity				
Balance as of April 1, 2017	-	124,489	1,011,610	1,175,897	(4,469)	1,171,428
Profit for the year	-	-	60,282	60,282	(471)	59,811
Other comprehensive income (loss) for the year	1,620	2,078	-	2,078	-	2,078
Total comprehensive income (loss) for the year	1,620	2,078	60,282	62,361	(471)	61,890
Purchase of treasury shares	-	-	-	(50,085)	-	(50,085)
Cancellation of treasury shares	-	(74)	(75)	304	-	304
Dividends	-	-	(46,430)	(46,430)	-	(46,430)
Acquisition of non-controlling interests	-	-	-	(9,064)	5,007	(4,057)
Transfer from other components of equity to retained earnings	(1,620)	(5,989)	5,989	-	-	-
Others	-	-	-	-	(8)	(8)
Total transactions with owners of the Company	(1,620)	(6,063)	(40,516)	(105,276)	4,998	(100,277)
Balance as of March 31, 2018	-	120,504	1,031,376	1,132,982	58	1,133,041

5) Consolidated Statement of Cash Flows

(Millions of Yen)

	Note	Year ended March 31, 2017	Year ended March 31, 2018
Cash flows from operating activities			
Profit before tax		87,788	81,021
Depreciation and amortization		47,373	46,680
Impairment loss		26,459	36,672
Financial income		(6,406)	(8,642)
Financial expenses		7,710	4,223
Share of (profit) loss of investments accounted for using the equity method		(162)	(320)
(Gain) loss on sale and disposal of non-current assets		449	(5,125)
(Increase) decrease in trade and other receivables		15,148	2,535
(Increase) decrease in inventories		(10,951)	(19,394)
Increase (decrease) in trade and other payables		(16,979)	238
Others, net		13,398	(9,755)
Subtotal		163,828	128,134
Interest and dividends received		4,289	4,516
Interest paid		(1,511)	(2,038)
Income taxes paid		(30,371)	(22,173)
Net cash flows from (used in) operating activities		136,234	108,439
Cash flows from investing activities			
Payments into time deposits		(492,441)	(388,376)
Proceeds from maturities of time deposits		404,416	488,576
Acquisition of securities		(180,376)	(128,492)
Proceeds from sale of securities		219,049	165,458
Acquisition of property, plant and equipment		(24,766)	(23,399)
Proceeds from sale of property, plant and equipment		2,403	139
Acquisition of intangible assets		(28,196)	(14,609)
Payments for loans receivable		(71)	(982)
Proceeds from collection of loans receivable		1,472	753
Others, net		1,719	9,501
Net cash flows from (used in) investing activities		(96,792)	108,568
Cash flows from financing activities			
Proceeds from bonds and borrowings		100,000	-
Repayments of bonds and borrowings		(20,000)	-
Purchase of treasury shares		(50,095)	(50,085)
Proceeds from sale of treasury shares		1	1
Dividends paid		(43,889)	(46,420)
Others, net	32	(1,038)	(5,262)
Net cash flows from (used in) financing activities		(15,022)	(101,766)
Net increase (decrease) in cash and cash equivalents		24,419	115,241
Cash and cash equivalents at the beginning of the year	8	222,159	246,050
Effect of exchange rate changes on cash and cash equivalents		(527)	(3,590)
Cash and cash equivalents at the end of the year	8	246,050	357,702

Notes to the Consolidated Financial Statements

1. Reporting Entity

Daiichi Sankyo Company, Limited (the “Company”) is a public company domiciled in Japan. The addresses of its registered head office and principal business locations are disclosed on the Company’s website (<https://www.daiichisankyo.co.jp>). The Daiichi Sankyo Group consists of 57 companies including the Company, 53 subsidiaries and 3 associates (collectively the “Group”) and is engaged in manufacturing and marketing of pharmaceutical products.

The Group’s consolidated financial statements for the year ended March 31, 2018 were approved on June 18, 2018 by Sunao Manabe, Representative Director, President and COO.

2. Basis of Preparation

(1) Compliance with International Financial Reporting Standards

The consolidated financial statements of the Group have been prepared in accordance with International Financial Reporting Standards (“IFRS”) under Article 93 of the Ordinance on Terminology, Forms, and Preparation Methods of Consolidated Financial Statements, as the Group meets the criteria of a “Specified Entity” defined under Article 1-2 of this ordinance.

(2) Basis of Measurement

The Group’s consolidated financial statements have been prepared on a historical cost basis except for certain financial instruments and other items as described in Note 3 “Significant Accounting Policies.”

(3) Functional Currency and Presentation Currency

The Group’s consolidated financial statements are presented in Japanese Yen, which is the functional currency of the Company. All financial information presented in Japanese Yen has been rounded down to the nearest million Japanese Yen.

(4) Early Adoption of New Accounting Standards

The Group has early adopted IFRS 9 “Financial Instruments” (issued in November 2009, amended in October 2010 and December 2011) from the date of IFRS transition (April 1, 2012).

IFRS 9 replaces existing guidance in IAS 39 “Financial Instruments: Recognition and Measurement” and classifies financial instruments into two measurement categories, amortized cost and fair value. The change in fair value of financial instruments which have initially been measured at fair value is recognized in profit or loss. However, the change in fair value of equity instruments can be recognized through other comprehensive income, except for financial instruments held for trading.

(5) Changes in Accounting Policies

The significant accounting policies adopted in preparing the consolidated financial statements of the Group have not changed from the prior year except for the adoption of the following new and amended accounting standards. In the year ended March 31, 2018, the Group adopted the following accounting standards in accordance with their effective date. These new and amended accounting standards did not have a material impact on the consolidated financial statements.

IFRS		Overview
IAS 7	Statement of Cash Flows	Amendment to disclosure requirements for changes in liabilities arising from financing activities
IAS 12	Income Taxes	Amendment to clarify the recognition of deferred tax assets for unrealized losses

3. Significant Accounting Policies

(1) Basis of Consolidation

The Group's consolidated financial statements include the financial statements of the Company and its subsidiaries and the Group's interests in equity-accounted associates.

a. Subsidiaries

A Subsidiary is an entity that is controlled by the Group. The Group controls an entity if the Group has power over the entity, exposure, or rights, to variable returns from its involvement with the entity and the ability to use its power over the entity to affect the amount of its returns. Consolidation of a subsidiary begins from the date the Group obtains control of the subsidiary and cease when the Group loses control of the subsidiary. Changes in a parent's ownership interest in a subsidiary that occur after obtaining the control over the subsidiary and that do not result in the parent losing control of the subsidiary are accounted for as equity transactions.

All intra-group balances and transactions, and any unrealized gains and losses arising from intra-group transactions, are eliminated in preparing the consolidated financial statements.

b. Associates

An associate is an entity over which the Group has significant influence but is not a subsidiary of the Group. Significant influence is the power to participate in the financial and operating policy decisions of the investee but is not control or joint control of those policies.

An investment is accounted for using the equity method from the date on which the Group has the significant influence until the date on which it ceases to have the significant influence over the investment.

When significant influence over an associate is lost, and if there is still remaining ownership interest, the remaining equity interest is measured at fair value. The difference between the fair value and the carrying value at the date on which the equity method is discontinued, is recognized in profit or loss.

Investment in associates includes acquired goodwill.

(2) Business Combinations

Business combinations are accounted for using the acquisition method. The acquisition cost is measured as the sum of the consideration transferred, the amount of non-controlling interest in the acquiree, and in the case of an acquisition achieved in stages, the fair value of the previously held equity interest at the date of acquisition. The consideration transferred is measured at fair value at the date of acquisition. Non-controlling interests are measured either at fair value or at the proportionate share of the acquiree's identifiable net assets for each business combination.

The excess of the acquisition cost over the Group's share of the acquiree's identifiable assets, liabilities, and contingent liabilities at fair value is recognized as goodwill. When the aggregate amount of the acquiree's identifiable assets, liabilities and contingent liabilities exceeds the acquisition cost, the resulting gain is recognized in profit or loss on the date of acquisition. Acquisition related costs are recognized as expenses in the period they are incurred.

(3) Foreign Currency Translation

Foreign currency transactions are translated into the functional currency using the exchange rates at the dates of the transactions. Foreign currency monetary assets and liabilities are translated into the functional currency using the exchange rates at the end of the reporting period and the exchange differences arising on the settlement of monetary items or on translating monetary items are generally recognized in profit or loss. However, exchange differences arising from the translation of financial assets measured at fair value through other comprehensive income and cash flow hedges are recognized in other comprehensive income.

Assets and liabilities of foreign operations (including goodwill and fair value adjustments arising on the acquisition of foreign operations) are translated into the presentation currency at the closing rate at the end of the reporting period. Income and expenses of foreign operations are translated into the presentation currency at the average exchange rate for the period. When a subsidiary's functional currency is the currency of a hyperinflationary economy, adjustments are made to its separate financial statements to reflect current price levels, and income and expenses of the subsidiary are translated into the presentation currency at the closing rate at the end of the reporting period.

Exchange differences arising from translation of financial statements of foreign operations are recognized in other comprehensive income after the date of transition to IFRS. On the disposal of the entire interest in a foreign operation, or on the partial disposal of the interest in a foreign operation that involves the loss of control of a subsidiary or loss of significant influence over an associate, the cumulative amount of the exchange differences relating to that foreign operation, recognized in other comprehensive income and accumulated as a separate component of equity, is reclassified to profit or loss as a part of gain or loss on disposal.

(4) Financial Instruments

a. Non-derivative Financial Assets

i) Initial recognition and measurement

Financial assets are classified as financial assets measured at amortized cost or financial assets measured at fair value at initial recognition.

Financial assets are classified as financial assets measured at amortized cost if both of the following conditions are met.

- (a) The asset is held within a business model whose objective is to hold assets in order to collect contractual cash flows.
- (b) The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

Otherwise, they are classified as financial assets measured at fair value.

For financial assets measured at fair value, each equity instrument, except for an equity instrument held for trading, which must be measured at fair value through profit or loss, is designated as financial assets measured at fair value through profit or loss or as financial assets measured at fair value through other comprehensive income. Such designations are applied consistently. In the case of financial assets not measured at fair value through profit or loss, they are measured at the fair value plus transaction costs that are attributable to the acquisition of financial assets.

Trade and other receivables are recognized on the date when they are incurred. All other financial assets are recognized on the contract date when the Group becomes a party to the contractual provisions of the instruments.

ii) Subsequent measurement

After initial recognition, financial assets are measured based on their classification as follows:

(a) Financial assets measured at amortized cost

Financial assets measured at amortized cost are measured at amortized cost using the effective interest method.

(b) Financial assets measured at fair value

Financial assets measured at fair value are measured at fair value.

Changes in the fair value of financial assets measured at fair value are recognized in profit or loss.

However, changes in the fair value of equity instruments designated as financial assets measured at fair value through other comprehensive income are recognized in other comprehensive income, and the accumulated amount of other comprehensive income is transferred to retained earnings when equity instruments are derecognized or the decrease in fair value compared to its acquisition cost is significant.

iii) Derecognition

Financial assets are derecognized when the contractual rights to the cash flows from the asset expire, or are transferred in a transaction in which substantially all the risks and rewards of ownership of the asset are transferred to another entity.

b. Impairment of Financial Assets

At the end of each reporting period, financial assets measured at amortized cost are assessed to determine whether there is any objective evidence of impairment. Objective evidence that financial assets measured at amortized cost are impaired includes significant financial difficulty of the debtor or a group of debtors, a default or delinquency in interest or principal payments, and bankruptcy of the debtor.

The Group assesses whether objective evidence of impairment exists individually for financial assets that are individually significant, and collectively for financial assets that are not individually significant.

If there is objective evidence that impairment losses on financial assets measured at amortized cost have been incurred, the amount of the loss is measured as the difference between the assets' carrying amount and the present value of estimated future cash flows.

When impairment is recognized, the carrying amount of the financial asset is reduced through use of allowance for doubtful accounts and impairment losses are recognized in profit or loss. The carrying amount of financial assets measured at amortized cost is reduced directly when they are expected to become uncollectible in the future and all collaterals are implemented or transferred to the Group. If, in a subsequent period, the amount of the impairment loss decreases and the decrease is related to an event occurring after the impairment is recognized, the previously recognized impairment losses are reversed by adjusting the allowance for doubtful account and the reversal is recognized in profit or loss.

c. Non-derivative Financial Liabilities

i) Initial recognition and measurement

Financial liabilities are classified as financial liabilities measured at amortized cost or financial liabilities measured at fair value through profit or loss at initial recognition. At initial recognition, financial liabilities are measured at fair value and, in the case of financial liabilities at amortized cost, the transaction costs that are directly attributable to the issue of the financial liabilities are deducted.

ii) Subsequent measurement

After initial recognition, financial liabilities are measured based on the classification as follows:

(a) Financial liabilities measured at amortized cost

Financial liabilities measured at amortized cost are measured at amortized cost using the effective interest method. Amortization using the effective interest method and gains or losses arising from termination of recognition are recognized in profit or loss.

(b) Financial liabilities measured at fair value through profit or loss

Financial liabilities measured at fair value through profit or loss are measured at fair value through profit or loss.

iii) Derecognition

Financial liabilities are derecognized when the obligation is discharged, cancelled or expired.

d. Offsetting Financial Assets and Liabilities

Financial assets and financial liabilities are offset only when the Group has a legally enforceable right to offset the recognized amounts and intends to settle on a net basis or to realize the asset and settle the liability simultaneously.

e. Derivative and Hedge Accounting

Derivatives are utilized to hedge foreign currency risk and interest rate risk. The derivatives primarily used by the Group include forward foreign exchange contracts and interest-rate swaps.

For derivatives designated as hedging instruments, at the inception of a hedge, the Group formally designates and documents the relationship between the hedging instrument and hedged item, and the risk management objective and strategy for undertaking the hedge are established.

On an ongoing basis, the Group assesses whether the hedging instrument is highly effective in achieving offsetting changes in fair values or cash flows of the hedged item attributable to the hedged risk throughout the period for which the hedge is designated.

Derivatives are initially recognized at fair value with transaction costs recognized in profit or loss when they are incurred. After initial recognition, derivatives are measured at fair value.

Hedges that meet the criteria for hedge accounting are accounted for as follows:

i) Fair value hedges

Changes in the fair value of the hedging instruments are recognized in profit or loss. Changes in the fair value of hedged items attributable to the hedged risks are recognized in profit or loss, adjusting the carrying amount of the hedged item.

ii) Cash flow hedges

The effective portion of changes in fair value of hedging instruments is recognized in other comprehensive income, while the ineffective portion is recognized immediately in profit or loss. The cumulative amounts of changes in fair values of hedging instruments recognized in other comprehensive income are reclassified from equity to profit or loss in the same period or periods when the hedged forecast cash flows or hedged items affect profit or loss. If hedged items result in the recognition of non-financial assets or non-financial liabilities, the cumulative amounts recognized in other comprehensive income as equity are accounted for as adjustments in the carrying amount of the non-financial assets or non-financial liabilities. When forecast transactions or firm commitments are no longer expected to occur, any related cumulative gain or loss that has been recognized in other comprehensive income is reclassified from equity to profit or loss. When hedging instruments expire or are sold, terminated or exercised without the replacement or rollover of other hedging instruments, or when the hedge designation is revoked, the cumulative amounts that have been recognized in other comprehensive income are continued to be recognized in other comprehensive income until the forecast transactions or firm commitments are incurred or are no longer expected to occur.

(5) Cash and Cash Equivalents

Cash and cash equivalents comprise cash on hand, readily available bank deposits, and short-term, highly liquid investments having maturities of three months or less that are readily convertible to known amounts of cash and subject to an insignificant risk of changes in value.

(6) Inventories

Inventories are measured at the lower of cost and net realizable value. Costs of inventories comprise cost of raw materials, direct labor and other costs directly attributable to the inventories and cost of related production overheads. The cost of inventories is assigned by using the weighted average cost formula. Net realizable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale.

(7) Property, Plant and Equipment

Property, plant and equipment is carried at cost less any accumulated depreciation and any impairment losses.

The cost of an item of property, plant and equipment include any costs directly attributable to the acquisition of the asset, costs of dismantlement, removal and restoration as well as borrowing costs eligible for capitalization.

An item of property, plant and equipment, except for land, is depreciated by the straight-line method based on the estimated useful life of the asset. The estimated useful lives of major items of property, plant and equipment are as follows:

- Buildings and structures: 15 to 50 years
- Machinery and vehicles: 4 to 8 years

The depreciation method, the residual value and the useful life of an item of property, plant and equipment are reviewed at least annually and adjusted as necessary.

(8) Goodwill and Intangible Assets

a. Goodwill

Goodwill is measured at cost less accumulated impairment loss and is not amortized. Goodwill arising from a business combination is allocated to cash-generating units that are expected to benefit from the synergies of the business combination.

b. Intangible Assets

Intangible assets are carried at cost less any accumulated amortization and any accumulated impairment loss.

The cost of a separately acquired intangible asset is measured at cost and the cost of an intangible asset acquired in a business combination is measured at its fair value at the acquisition date.

Internally generated research expenditure is recognized as an expense when it is incurred. Internally generated development expenditure is recognized as an intangible asset if all the criteria for capitalization can be demonstrated. However, due to the uncertainties relating to the research and development duration and process, it is considered that the criteria for capitalization are not met until marketing approval from a regulatory authority is obtained. Therefore, internally generated development expenditure is recognized as an expense when it is incurred. Acquisition cost and development expenditure of software for internal use is recognized as an intangible asset if it can be demonstrated that the asset will generate probable future economic benefits.

Intangible assets with finite useful lives are amortized by the straight-line method based on the estimated useful life of the asset. The estimated useful lives of major items of intangible assets are as follows:

- Commercial rights: 5 to 14 years

The amortization method, the residual value and the useful lives of intangible assets are reviewed at least annually and adjusted as necessary.

(9) Leases

A lease is classified as a finance lease if it transfers substantially all the risks and rewards incidental to ownership of an asset, otherwise it is classified as an operating lease.

Under finance lease transactions, finance leases are recognized as leased assets and lease obligations at the lower of the fair value of the leased property and the present value of the minimum lease payments.

Leased assets are depreciated by the straight-line method over the shorter of the lease term and the useful life.

Under operating lease transactions, lease payments are recognized as an expense on a straight-line basis over the lease term.

(10) Impairment of Non-financial Assets

The Group assesses annually whether there is any indication that a non-financial asset or cash-generating unit that generates cash inflows may be impaired.

If there is any indication that an asset or cash-generating unit may be impaired, the recoverable amount of the asset is estimated. Goodwill, intangible assets with indefinite lives, and intangible assets not yet available for use are tested for impairment annually or at any time there is an indication that an asset may be impaired.

The recoverable amount of an asset or a cash-generating unit is the higher of its fair value less costs of disposal and its value in use, which is calculated based on the risk-adjusted future cash flows discounted by an appropriate discount rate.

If the carrying amount of an asset or a cash-generating unit exceeds the recoverable amount, an impairment loss is recognized in profit or loss and the carrying amount is reduced to the recoverable amount.

An impairment loss recognized for goodwill is not reversed in a subsequent period. It is assessed whether there is any indication that an impairment loss recognized in prior periods for an asset other than goodwill may no longer exist or may have decreased. If any such indication exists, the recoverable amount of the asset or cash-generating unit is estimated. If the recoverable amount exceeds the carrying amount of the asset or cash-generating unit, an impairment loss recognized in prior periods is reversed and the carrying amount of the asset is increased to the recoverable amount. The reversal of the impairment loss is recognized in profit or loss. The increased carrying amount of an asset other than goodwill attributable to a reversal of an impairment loss does not exceed the carrying amount that would have been determined (net of amortization or depreciation) if no impairment loss had been recognized for the asset in prior years.

(11) Non-current Assets Held for Sale and Discontinued Operations

A non-current asset, or disposal group comprising assets and liabilities, is classified as asset held for sale if its carrying amount will be recovered primarily through sale rather than continuing use. The asset or disposal group is classified as held for sale only if it is available for immediate sale in its present condition, and the sale is highly probable meaning that the appropriate level of management of the Group is committed to the sale and principally that the sale is expected to be completed within one year. After the asset or disposal group is classified as held for sale, it is measured at the lower of its carrying amount and fair value less costs to sell, and is not depreciated or amortized. Discontinued operations include a component of an entity that either has been disposed of or is classified as held-for-sale, and represents a separate major line of business or geographic area of operations.

(12) Employee Benefits

a. Post-employment Benefits

i) Defined benefit plans

The present value of defined benefit obligations and related current service cost and, where applicable, past service cost are determined using the projected unit credit method for each plan separately.

The discount rate is determined by reference to market yields at the end of the reporting period on high-rated corporate bonds, reflecting the estimated timing of benefit payments.

Past service costs are recognized in profit or loss as incurred.

Actuarial gains and losses are recognized in other comprehensive income in the period when they are incurred and transferred to retained earnings immediately.

ii) Defined contribution plans

The contributions to defined contribution plans are recognized as expenses when the related service is rendered by the employees.

b. Others

Short-term employee benefits are not discounted and are recognized as expenses when the related service is rendered by the employees. The expected costs of accumulating short-term compensated absences are recognized as liabilities when the Group has present legal or constructive obligations to pay as a result of past employee service and when reliable estimates of the obligation can be made.

(13) Provisions

A provision is recognized when there is a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation.

When the effect of the time value of money is material, the amount of a provision is measured at the present value of the expenditures expected to be required to settle the obligation. The present value is determined by using the pre-tax discount rate that reflects current market assessments of the time value of money and the risks inherent in the liabilities. The increase in the carrying amount of a provision reflecting the passage of time is recognized as a financial expense.

(14) Treasury Shares

Treasury shares are recognized as a deduction from equity. No gain or loss is recognized on the purchase, sale or cancellation of the treasury shares. Any difference between the carrying amount and the consideration paid is recognized in capital surplus.

(15) Share-based Payments

The Company and certain of its subsidiaries have implemented stock option plans and restricted share-based remuneration plans as equity-settled share-based payment plans. The stock options are measured at the fair value at the date of grant using the Black-Scholes option pricing model, and recognized as expenses over the vesting period, with a corresponding increase in equity. The restricted shares are measured at the fair value at the date of grant based on the fair value of the equity instrument granted, and recognized as expenses over the vesting period, with a corresponding increase in equity.

In addition, the Group issues share appreciation rights to employees as a cash-settled share-based payment. For the cash-settled share-based payments, the fair value of the amount of payments is recognized as an expense with a corresponding liability. The change in the fair value of the liability at each reporting date is recognized in profit or loss until the liability is settled.

(16) Revenue

a. Sales of finished goods and merchandise

Revenue from the sale of finished goods and merchandise is recognized when all the following conditions have been satisfied:

- the significant risks and rewards of ownership of the finished goods and merchandise have been transferred to the buyer;
- the Group retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;
- the amount of revenue can be measured reliably;
- it is probable that the economic benefits associated with the transaction will flow to the entity; and
- the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Revenue is measured at the fair value of the consideration received or receivable. Trade discounts, cash discounts, rebates and returns are recognized in the period when the revenue that they result from is recognized, and deducted from revenue.

Taxes such as consumption taxes, sales taxes and value added taxes are excluded from revenue.

b. Rendering of Services

Revenue from rendering of services is recognized when the service is rendered to customers outside of the Group.

c. Royalty Income

Revenue arising from royalties is recognized on an accrual basis in accordance with the substance of the relevant agreement.

(17) Government Grants

Government grants are recognized at fair value when there is reasonable assurance that the Group complies with the conditions attached to them and that the grants will be received.

Government grants which are intended to compensate specific costs are recognized in profit or loss on a systematic basis over the period in which the Group recognizes the corresponding expenses.

Government grants related to assets are recognized as deferred revenue, and recognized in profit or loss on a systematic basis over the estimated useful lives of the relevant assets.

(18) Income Taxes

Income taxes comprise current and deferred income taxes.

Income taxes are recognized in profit or loss, except to the extent that the taxes arise from transactions or events which are recognized either in other comprehensive income or directly in equity, or the taxes arise from business combinations.

Current income taxes are measured at the amount expected to be paid to or recovered from the taxation authorities, using the tax rates that have been enacted or substantively enacted by the end of the reporting period.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply to the period when the asset is realized or the liability is settled, based on tax rates that have been enacted or substantively enacted by the end of the reporting period. Deferred tax assets and liabilities are recognized for temporary differences between the carrying amount of assets or liabilities for accounting purpose and the tax basis, and unused tax losses and tax credits.

Deferred tax assets are recognized to the extent that it is probable that future taxable profit will be available against which they can be utilized.

When uncertainties exist if the taxing authorities will accept a particular tax treatment, the said uncertainties are reflected when determining the taxable profit, the carrying amount for the tax basis, unused tax losses and tax credits, and the tax rate.

Deferred tax assets and liabilities are not recognized for temporary differences that arise from the initial recognition of goodwill or that arise from the initial recognition of assets or liabilities in transactions which are not business combinations and, at the time of transaction, affect neither accounting profit nor taxable profit or tax loss.

Deferred tax liabilities for taxable temporary differences associated with investments in subsidiaries and associates are recognized, except to the extent that the Group is able to control the timing of the reversal of the temporary differences and that it is probable that the temporary differences will not reverse in the foreseeable future. Deferred tax assets for deductible temporary differences arising from investments in subsidiaries and associates are recognized only to the extent that it is probable that the temporary differences will reverse in the foreseeable future and taxable profit will be available against which the temporary differences can be utilized.

Deferred tax assets and deferred tax liabilities are offset if there is a legally enforceable right to offset current tax assets against current tax liabilities and the deferred tax assets and the deferred tax liabilities relate to income taxes levied by the same taxation authority on the same taxable entity.

4. Significant Accounting Judgments, Estimates and Assumptions

The preparation of these consolidated financial statements requires management of the Group to make judgments, estimates and assumptions that affect the amount of reported income, expenses, assets and liabilities as well as disclosure of contingent liabilities. However, due to uncertainty in the estimates and assumptions, it is possible that significant adjustments to carrying amounts of assets and liabilities may be required in future periods.

Significant items that required management to make estimates and judgments are as follows:

- Contingent consideration (Note 7. Business Combination)
- Impairment of non-financial assets (Note 13. Property, Plant and Equipment, Note 14. Goodwill and Intangible Assets)
- Useful lives of intangible assets (Note 14. Goodwill and Intangible Assets)
- Recoverability of deferred tax assets and uncertain tax positions (Note 16. Income Taxes)
- Provisions (Note 19. Provisions)
- Measurement of defined benefit obligations (Note 20. Employee Benefits)
- Measurement of share-based payments (Note 28. Share-based Payments)
- Fair value of financial instruments (Note 29. Financial Instruments)
- Contingent liabilities (Note 35. Contingent Liabilities)

5. Standards and Interpretations Issued but Not Yet Adopted

The major new and revised standards and interpretations that the Group has not early adopted are set out below.

The accounting standards and interpretations which will be adopted in the year ending March 31, 2019 are not expected to have a material impact on the consolidated financial statements. The Group is currently evaluating the impact of applying standards and interpretations which will be adopted by the Group in the year ending March 31, 2020 and thereafter to the consolidated financial statements, and it is not yet estimable.

IFRS		Mandatory application (from years beginning)	To be applied by the Group (year ending)	Overview
IFRS 2	Share-based Payment	January 1, 2018	March 31, 2019	Amendment to classification and measurement of share based payments
IFRS 9	Financial Instruments	January 1, 2018	March 31, 2019	Amendment to rules for general hedge accounting Limited amendment to classification and measurement of financial assets and implementation of expected loss model
IFRS 15	Revenue from Contracts with Customers	January 1, 2018	March 31, 2019	Amendment to accounting for revenue
IAS 40	Investment Property	January 1, 2018	March 31, 2019	Amendment to clarify the rules for transfers of investment property
IFRIC 22	Foreign Currency Transactions and Advance Consideration	January 1, 2018	March 31, 2019	Amendment to the exchange rate to be used on initial recognition of a related asset, expense or income when an entity has received or paid advance consideration in a foreign currency
IFRS 9	Financial Instruments	January 1, 2019	March 31, 2020	Rules for classification of debt instruments containing prepayment features with negative compensation
IFRS 16	Leases	January 1, 2019	March 31, 2020	Amendment to accounting for leases
IAS 19	Employee Benefits	January 1, 2019	March 31, 2020	Clarification of accounting for a plan amendment, curtailment or settlement, which occurs during the annual reporting period
IAS 28	Investments in Associates and Joint Ventures	January 1, 2019	March 31, 2020	Clarification of rules for financial instruments in an associate or joint venture to which the equity method is not applied
IFRIC 23	Uncertainty over Income Tax Treatments	January 1, 2019	March 31, 2020	Amendment to clarify the accounting for income tax treatments that contains uncertainty
IFRS 17	Insurance Contracts	January 1, 2021	March 31, 2022	Amendment to establish consistent accounting treatment for insurance contracts
IFRS 10	Consolidated Financial Statements	-	-	Amendment to accounting for sale of assets to associates
IAS 28	Investments in Associates and Joint Ventures			

6. Operating Segment Information

(1) Reportable Segments

The Group consists of a single segment, "Pharmaceutical Operation," so disclosure of reportable segments is omitted.

(2) Information about products and services

Sales by products and services were as follows:

(Millions of Yen)

Item name	Year ended March 31, 2017		Year ended March 31, 2018		Increase / (decrease)	
	Amount	Ratio (%)	Amount	Ratio (%)	Amount	Ratio (%)
Prescription drugs	885,573	92.7	884,907	92.2	(665)	(0.1)
Healthcare (OTC) products	66,882	7.0	72,943	7.6	6,060	9.1
Others	2,668	0.3	2,344	0.2	(324)	(12.1)
Total	955,124	100.0	960,195	100.0	5,070	0.5

(3) Information by geographical area

As of and for the year ended March 31, 2017

(Millions of Yen)

	Japan	North America	Europe	Other regions	Consolidated
Revenue from external customers (note 1)	579,883	235,316	71,021	68,903	955,124
Non-current assets (note 2)	297,805	188,120	18,877	8,459	513,263

As of and for the year ended March 31, 2018

(Millions of Yen)

	Japan	North America	Europe	Other regions	Consolidated
Revenue from external customers (note 1)	618,308	185,751	79,566	76,568	960,195
Non-current assets (note 2)	265,787	174,969	17,806	8,400	466,963

Notes:

1. Revenue from external customers is classified according to the geographical location of customers.
2. Non-current assets are primarily presented based on the geographical location of assets, and are comprised of property, plant and equipment, goodwill and intangible assets.

(4) Information on major customers

External customers that account for more than 10% of the net sales reported on the Consolidated Statement of Profit or Loss are as follows:

(Millions of Yen)

Name of customer	Year ended March 31, 2017	Year ended March 31, 2018
Alfresa Holdings Corporation and its group companies	190,637	199,809
Suzuken Co., Ltd. and its group companies	88,539	98,603
McKesson Corporation	109,800	62,276

7. Business Combination

(1) Significant business combination

Year ended March 31, 2017

There were no significant business combinations for the year ended March 31, 2017.

Year ended March 31, 2018

There were no significant business combinations for the year ended March 31, 2018.

(2) Contingent consideration

The contingent consideration in the business combination relates to commercial milestone for Ambit Biosciences Corporation's drug candidate for acute myeloid leukemia which is currently in phase III clinical trials (Generic name: Quizartinib, Development code: AC220) and is measured at its acquisition date fair value. Maximum potential future cash outflows associated with the contingent consideration total 10,127 million yen (undiscounted).

The exposure to foreign currency exchange risks at the reporting date is 54,209 thousand U.S. dollar. The impact of a 1% appreciation in the Yen against the U.S. dollar on profit before tax is 57 million yen at the reporting date.

The fair value hierarchy level for this contingent consideration is level 3. The fair value change of contingent consideration is recognized in "Financial expenses." The fair value hierarchy is summarized in Note 29 "Financial Instruments."

Reconciliation of the movement in the contingent consideration which is classified as level 3 from the opening balances to the ending balances is as follows:

(Millions of Yen)

	Year ended March 31, 2017	Year ended March 31, 2018
Balance at the beginning of the year	2,859	6,066
Increase arising from business combination	-	-
Changes in fair value during the period	3,219	14
Settled during the period	-	-
Exchange differences	(12)	(320)
Balance at the end of the year	6,066	5,760

8. Cash and Cash Equivalents

Details of "Cash and cash equivalents" are as follows:

(Millions of Yen)

	As of March 31, 2017	As of March 31, 2018
Cash and bank deposits	225,535	258,211
Short-term investments	20,515	99,490
Total	246,050	357,702

9. Trade and Other Receivables

Details of "Trade and other receivables" in the consolidated statement of financial position are as follows:

(Millions of Yen)

	As of March 31, 2017	As of March 31, 2018
Notes and accounts receivable - trade	209,146	211,222
Other receivables	23,200	20,759
Allowance for doubtful accounts	(479)	(453)
Total	231,867	231,529

10. Other Financial Assets

(1) Breakdown of Other Financial Assets

Breakdown of “Other financial assets” is as follows:

a. Current Assets

(Millions of Yen)

	As of March 31, 2017	As of March 31, 2018
Financial assets measured at amortized cost:		
Bank deposits	284,064	192,085
Loans receivable	492	501
Bonds	122,876	102,777
Others	240	124
Financial assets measured at fair value through profit or loss:		
Bonds	8,976	1,257
Others	136,244	132,633
Total	552,896	429,380

Note:

“Others” in “Financial assets measured at fair value through profit or loss” are foreign-currency bank deposits embedding forward foreign exchange contracts.

b. Non-current Assets

(Millions of Yen)

	As of March 31, 2017	As of March 31, 2018
Financial assets measured at amortized cost:		
Loans receivable	741	888
Bonds	10	-
Others	7,930	45,891
Financial assets measured at fair value through profit or loss:		
Bonds	1,583	554
Others	7,933	9,315
Financial assets measured at fair value through other comprehensive income:		
Equity securities	120,005	122,479
Others	2,650	47
Total	140,856	179,177

(2) Financial assets measured at fair value through other comprehensive income

Details of financial assets measured at fair value through other comprehensive income are as follows:

(Millions of Yen)

Equity Securities	Fair Value	
	As of March 31, 2017	As of March 31, 2018
Ono Pharmaceutical Co., Ltd.	8,042	11,496
Maruho Co., Ltd.	5,723	9,787
Shizuoka Bank, Ltd.	8,464	9,399
Shin-Etsu Chemical Co., Ltd.	7,431	8,480
Others	92,993	83,362

Note:

Equity securities are held to reinforce transactions and business relationships. These securities are designated as financial assets measured at fair value through other comprehensive income.

(3) Derecognition of Financial Assets Measured at Fair value through Other Comprehensive Income

In the years ended March 31, 2017 and 2018, the Group disposed and derecognized some financial assets measured at fair value through other comprehensive income to improve the efficiency of assets by reassessing the business relationships. Their fair value and accumulated gains and losses at the time of disposal are as follows:

(Millions of Yen)

	Year ended March 31, 2017		Year ended March 31, 2018	
	Fair value	Accumulated gains (losses)	Fair value	Accumulated gains (losses)
Equity securities	17,257	9,315	14,410	9,838
Others	-	-	2,262	(2,764)

Note:

When financial assets measured at fair value through other comprehensive income are derecognized, gains and losses accumulated in other comprehensive income are reclassified to retained earnings.

11. Inventories

(1) Details of Inventories

Details of "Inventories" in the consolidated statement of financial position are as follows:

(Millions of Yen)

	As of March 31, 2017	As of March 31, 2018
Merchandise and finished goods	108,785	122,921
Work in process	16,500	19,409
Raw materials	27,852	30,254
Total	153,138	172,586

Notes:

1. Inventories recognized as expenses and included in "Cost of sales" in the consolidated statement of profit or loss for the years ended March 31, 2017 and 2018 are 285,611 million yen and 300,885 million yen, respectively.
2. Write-down of inventories recognized during the period and included in "Cost of sales" in the consolidated statement of profit or loss for the years ended March 31 2017 and 2018 are 3,621 million yen and 6,697 million yen, respectively.

12. Assets Held for Sale and Liabilities Directly Associated with Assets Held for Sale

Details of “Assets held for sale” and “Liabilities directly associated with assets held for sale” on the consolidated statement of financial position are as follows:

(Millions of Yen)

	As of March 31, 2017	As of March 31, 2018
Assets held for sale		
Property, plant and equipment	825	-
Other non-current assets	2,548	-
Total	3,374	-
Liabilities directly associated with assets held for sale		
Trade and other payables	721	-
Other financial liabilities	95	-
Deferred tax liabilities	241	-
Total	1,058	-

Note:

Assets held for sale and liabilities directly associated with assets held for sale as of March 31, 2017 are mainly investment properties held for rent owned by the Group, which were sold in the year ended March 31, 2018.

13. Property, Plant and Equipment

(1) Reconciliation of carrying amount

Reconciliation of the carrying amount and details of acquisition cost, accumulated depreciation and accumulated impairment loss of “Property, plant and equipment” on the consolidated statement of financial position are as follows:

a. Acquisition cost

(Millions of Yen)

	Land, buildings and structures	Machinery and vehicles	Tools, furniture and fixtures	Construction in progress	Total
Balance as of April 1, 2016	326,908	224,351	95,663	29,180	676,103
Individual acquisitions	12,480	24,872	5,195	22,260	64,807
Sales or disposals	(5,637)	(8,780)	(2,314)	(47)	(16,780)
Reclassification to assets held for sale	-	(1,987)	(48)	-	(2,035)
Exchange differences	(671)	(739)	(643)	(262)	(2,315)
Other increases and decreases	691	67	(64)	(40,746)	(40,052)
Balance as of March 31, 2017	333,770	237,783	97,788	10,384	679,726
Individual acquisitions	9,369	9,740	7,211	26,706	53,028
Sales or disposals	(2,140)	(9,173)	(4,455)	-	(15,769)
Exchange differences	(284)	(224)	264	(90)	(335)
Other increases and decreases	1,024	297	(37)	(25,020)	(23,735)
Balance as of March 31, 2018	341,740	238,423	100,770	11,979	692,914

b. Accumulated depreciation and accumulated impairment loss

(Millions of Yen)

	Land, buildings and structures	Machinery and vehicles	Tools, furniture and fixtures	Construction in progress	Total
Balance as of April 1, 2016	175,397	169,650	80,886	-	425,934
Depreciation	12,350	12,427	6,031	-	30,809
Impairment loss	13,222	7,859	972	-	22,054
Sales or disposals	(4,054)	(7,777)	(2,240)	-	(14,072)
Reclassification to assets held for sale	-	(1,153)	(48)	-	(1,201)
Exchange differences	(283)	(635)	(482)	-	(1,402)
Other increases and decreases	(187)	(67)	85	-	(168)
Balance as of March 31, 2017	196,445	180,302	85,205	-	461,953
Depreciation	9,621	11,787	5,764	-	27,173
Sales or disposals	(1,781)	(8,514)	(4,416)	-	(14,712)
Exchange differences	(165)	124	161	-	120
Other increases and decreases	473	(10)	(29)	-	433
Balance as of March 31, 2018	204,593	183,689	86,685	-	474,968

c. Carrying amounts

(Millions of Yen)

	Land, buildings and structures	Machinery and vehicles	Tools, furniture and fixtures	Construction in progress	Total
Balance as of April 1, 2016	151,510	54,701	14,776	29,180	250,168
Balance as of March 31, 2017	137,325	57,480	12,582	10,384	217,772
Balance as of March 31, 2018	137,147	54,734	14,084	11,979	217,946

Note:

Depreciation of property, plant and equipment is included in “Cost of sales,” “Selling, general and administrative expenses,” and “Research and development expenses” in the consolidated statement of profit or loss.

(2) Impairment of Property, Plant and Equipment

The Group performed impairment testing for certain property, plant and equipment for which indicators of potential impairment were identified.

As a result of the impairment testing, impairment losses of 22,054 million yen were recognized for the year ended March 31, 2017, and recorded in “Cost of sales,” “Selling, general and administrative expenses,” and “Research and development expenses” in the consolidated statement of profit or loss.

The impairment losses for the year ended March 31, 2017 are mainly related to property, plant and equipment owned by Kitasato Daiichi Sankyo Vaccine Co., Ltd., the Group’s consolidated subsidiary, which is involved in the domestic vaccine business. The Group identified impairment indicators such as a decline in earnings related to the property, plant and equipment owned by Kitasato Daiichi Sankyo Vaccine Co., Ltd. and performed impairment testing for these assets. The Group measured the recoverable amounts based on the fair value less disposal costs, and taking into consideration that these property, plant and equipment are manufacturing equipment used only for manufacturing of vaccines, the recoverable amounts were assessed to be zero. As a result, the Group recognized a 20,991 million yen impairment loss for the year ended March 31, 2017. The breakdown of the impairment loss is as follows: 12,204 million yen for land, buildings and structures, 7,826 million yen for machinery and vehicles, and 960 million yen for tools, furniture and fixtures.

The level of the fair value hierarchy for the fair values used in the impairment testing is level 3. More information on the fair value hierarchy is described in Note 29. “Financial Instruments.”

(3) Finance Lease Contracts

Details of carrying amounts of property, plant and equipment held under finance lease contracts which are included in “Property, plant and equipment” in the consolidated statement of financial position are as follows:

(Millions of Yen)

	Land, buildings and structures	Machinery and vehicles	Tools, furniture and fixtures	Total
Balance as of April 1, 2016	183	2,475	13	2,671
Balance as of March 31, 2017	-	1,337	74	1,411
Balance as of March 31, 2018	-	1,349	49	1,398

14. Goodwill and Intangible Assets

(1) Reconciliation of Carrying Amount

Reconciliation of the carrying amount and details of acquisition cost, accumulated amortization and accumulated impairment loss of “Goodwill” and “Intangible assets” in the consolidated statement of financial position are as follows:

a. Acquisition cost

(Millions of Yen)

	Goodwill	Intangible Assets			
		Research and development	Commercial rights and trademarks	Software	Total
Balance as of April 1, 2016	78,691	110,986	246,367	25,001	382,355
Individual acquisitions	-	14,145	13,627	624	28,397
Sales or disposals	-	(2,503)	(14,563)	(410)	(17,477)
Exchange differences	(245)	(230)	(4,016)	(256)	(4,503)
Other increases and decreases	-	(21,094)	21,048	86	40
Balance as of March 31, 2017	78,446	101,303	262,463	25,045	388,812
Individual acquisitions	-	6,831	11,472	2,546	20,850
Sales or disposals	-	(33,939)	(1,343)	(880)	(36,162)
Exchange differences	(2,966)	(2,812)	(1,805)	(424)	(5,042)
Other increases and decreases	-	(288)	257	(852)	(883)
Balance as of March 31, 2018	75,479	71,093	271,045	25,434	367,574

b. Accumulated amortization and accumulated impairment loss

(Millions of Yen)

	Goodwill	Intangible Assets			
		Research and development	Commercial rights and trademarks	Software	Total
Balance as of April 1, 2016	-	-	153,018	18,941	171,959
Amortization	-	-	13,828	2,446	16,274
Impairment loss	-	2,503	1,804	96	4,404
Sales or disposals	-	(2,503)	(14,437)	(377)	(17,318)
Exchange differences	-	-	(3,620)	(215)	(3,836)
Other increases and decreases	-	-	(30)	314	283
Balance as of March 31, 2017	-	-	150,562	21,205	171,768
Amortization	-	-	17,871	1,418	19,290
Impairment loss	-	31,612	5,060	-	36,672
Sales or disposals	-	(31,612)	(1,334)	(874)	(33,821)
Exchange differences	-	-	597	(433)	164
Other increases and decreases	-	-	(31)	(6)	(37)
Balance as of March 31, 2018	-	-	172,726	21,310	194,036

c. Carrying amounts

(Millions of Yen)

	Goodwill	Intangible Assets			
		Research and development	Commercial rights and trademarks	Software	Total
Balance as of April 1, 2016	78,691	110,986	93,349	6,059	210,395
Balance as of March 31, 2017	78,446	101,303	111,901	3,839	217,044
Balance as of March 31, 2018	75,479	71,093	98,319	4,124	173,537

Note:

Amortization of intangible assets is included in “Cost of sales,” “Selling, general and administrative expenses” and “Research and development expenses” in the consolidated statement of profit or loss.

(2) Significant Goodwill and Intangible Assets

The carrying amount of goodwill in the consolidated statement of financial position at March 31, 2017 and 2018 included amounts related to the acquisition of Plexxikon Inc. of 32,853 million yen and 31,116 million yen, respectively, and amounts related to the acquisition of Ambit Biosciences Corporation of 19,310 million yen and 18,290 million yen, respectively.

The carrying amount of intangible assets mainly consists of:

- commercial rights of Zelboraf owned by Plexxikon Inc. of 26,948 million yen and 21,232 million yen at March 31, 2017 and 2018, respectively, which are amortized based on the straight-line method over a period of 11 years;
- commercial rights of MOVANTIK owned by Daiichi Sankyo Inc. of 18,873 million yen and 13,664 million yen at March 31, 2017 and 2018, respectively, which are amortized based on the straight-line method over a period of 11 years;
- in-process research and development of Pexidartinib owned by Plexxikon Inc. of 27,679 million yen and 26,216 million yen at March 31, 2017 and 2018, respectively; and
- in-process research and development of Quizartinib owned by Ambit Biosciences Corporation of 28,908 million yen and 27,380 million yen at March 31, 2017 and 2018, respectively.

(3) Research and Development Expenditure

Research expenses and development costs which do not meet the criteria for capitalization are expensed when incurred. The amount of expensed research and development expenditure is 214,347 million yen and 236,046 million yen for the years ended March 31, 2017 and 2018, respectively.

(4) Impairment of Goodwill

The carrying amounts of goodwill allocated to each cash-generating unit are as follows:

	(Millions of Yen)	
	As of March 31, 2017	As of March 31, 2018
Domestic pharmaceutical operations	22,309	22,309
Overseas pharmaceutical operations	56,137	53,170
Total	78,446	75,479

Impairment tests for major items of goodwill were performed as follows:

a. Plexxikon Inc. (Overseas pharmaceutical operations)

The recoverable amount was estimated based on value in use using the mid-term plan through 2022, which was approved by management, and the valuation included a terminal value after 2022.

The value in use was calculated using a pre-tax discount rate of 14.63% to 15.95% and exceeded the carrying amount, therefore no impairment loss was recognized at March 31, 2018. The value in use exceeds the carrying amount, and the Group determined that the possibility of the value in use becoming lower than the carrying amount is remote, even if the discount rate were to increase within a reasonable range.

b. Ambit Biosciences Corporation (Overseas pharmaceutical operations)

The recoverable amount was estimated based on value in use using the mid-term plan through 2022, which was approved by management, and the valuation included a terminal value after 2022.

The value in use was calculated using a pre-tax discount rate of 9.58% to 14.87% and exceeded the carrying amount, therefore no impairment loss was recognized at March 31, 2018. The value in use exceeded the carrying amount, and the Group determined that the possibility of the value in use becoming lower than the carrying amount is remote, even if the discount rate were to increase within a reasonable range.

(5) Impairment of Intangible Assets

The Group performed impairment testing for certain intangible assets for which the indicators of potential impairment were identified.

As a result of the impairment testing, impairment losses of 4,404 million yen and 36,672 million yen were recognized for the years ended March 31, 2017 and 2018, respectively, and recorded in “Cost of sales,” “Selling, general and administrative expenses,” and “Research and development expenses” in the consolidated statement of profit or loss.

The impairment loss for the year ended March 31, 2017 was mainly related to research and development assets. The Group recognized the impairment loss due to the decision to discontinue the development projects.

The Group recognized a 27,764 million yen impairment loss for the year ended March 31, 2018 because the Group terminated a development and commercialization agreement related to CL-108, a combination drug for the treatment of pain and opioid-induced nausea and vomiting (OINV). The recoverable amount of the intangible assets was measured using value in use, which was assessed to be zero.

15. Investments Accounted for Using the Equity Method

Summarized financial information of associates accounted for using the equity method is as follows:

(1) Statement of Financial Position

(Millions of Yen)

	As of March 31, 2017	As of March 31, 2018
Current assets	13,171	14,494
Non-current assets	808	948
Total assets	13,980	15,442
Current liabilities	10,590	11,439
Non-current liabilities	507	693
Total liabilities	11,098	12,133
Total equity	2,882	3,309

(2) Statement of Profit or Loss

(Millions of Yen)

	Year ended March 31, 2017	Year ended March 31, 2018
Revenue	37,094	38,609
Expenses	36,659	38,257
Profit for the year	434	351

16. Income Taxes

(1) Deferred Tax Assets and Liabilities

Sources of “Deferred tax assets” and “Deferred tax liabilities” are as follows:

Year ended March 31, 2017

(Millions of Yen)

	Balance as of April 1, 2016	Recognized in profit or loss	Recognized in other comprehensive income	Others	Balance as of March 31, 2017
Deferred tax assets					
Prepaid outsourced research expenses and co-development expenses	15,498	(2,779)	-	-	12,718
Depreciation and amortization	4,224	(1,192)	-	-	3,032
Unrealized gain and valuation loss of inventories	19,363	337	-	-	19,701
Unused tax losses	963	4,780	(1,800)	-	3,943
Accrued expenses	20,100	(4,313)	-	-	15,787
Post-employment benefit liabilities	8,920	(25)	(845)	-	8,049
Valuation loss of securities	2,322	(476)	439	-	2,286
Impairment loss	625	459	-	(309)	775
Others	27,988	1,164	-	-	29,152
Total	100,006	(2,044)	(2,206)	(309)	95,446
Deferred tax liabilities					
Intangible assets	34,413	1,986	-	-	36,399
Financial assets measured at fair value through other comprehensive income	31,659	-	(5,999)	-	25,659
Reserve for advanced depreciation of property, plant and equipment	9,127	(915)	-	(241)	7,970
Others	2,759	1,395	52	-	4,208
Total	77,959	2,466	(5,946)	(241)	74,238
Net balance	22,046	(4,511)	3,740	(67)	21,208

Notes:

1. The difference between the total amounts recognized in profit or loss and other comprehensive income in the table above and the total deferred income taxes in profit or loss and total income taxes recognized through other comprehensive income, respectively, relates to income tax expenses associated with foreign currency translation differences.
2. The Group records tax assets and liabilities for uncertain tax positions based on the most probable estimate. Amounts exposed to uncertainty (possibility of favorable outcome) as of March 31, 2017 are income taxes payable of 53,577 million yen and deferred tax of 64,442 million yen.

Year ended March 31, 2018

(Millions of Yen)

	Balance as of April 1, 2017	Recognized in profit or loss	Recognized in other comprehensive income	Others	Balance as of March 31, 2018
Deferred tax assets					
Prepaid outsourced research expenses and co-development expenses	12,718	606	-	-	13,325
Depreciation and amortization	3,032	(506)	-	-	2,525
Unrealized gain and valuation loss of inventories	19,701	(8,354)	-	-	11,347
Unused tax losses	3,943	(2,573)	-	-	1,370
Accrued expenses	15,787	607	-	-	16,394
Provisions for loss on litigation	-	11,607	-	-	11,607
Post-employment benefit liabilities	8,049	(515)	(626)	-	6,907
Valuation loss of securities	2,286	(120)	(602)	-	1,562
Impairment loss	775	(452)	-	309	632
Others	29,152	(2,991)	-	-	26,160
Total	95,446	(2,692)	(1,229)	309	91,833
Deferred tax liabilities					
Intangible assets	36,399	(16,725)	-	-	19,674
Financial assets measured at fair value through other comprehensive income	25,659	-	2,314	-	27,974
Reserve for advanced depreciation of property, plant and equipment	7,970	(573)	-	241	7,638
Long-term accounts receivable - other	-	11,425	-	-	11,425
Others	4,208	(722)	(26)	-	3,458
Total	74,238	(6,596)	2,287	241	70,171
Net balance	21,208	3,903	(3,517)	67	21,662

Notes:

1. The difference between the total amounts recognized in profit or loss and other comprehensive income in the table above and the total deferred income taxes in profit or loss and total income taxes recognized through other comprehensive income, respectively, relates to income tax expenses associated with foreign currency translation differences.
2. The Group records tax assets and liabilities for uncertain tax positions based on the most probable estimate. Amounts exposed to uncertainty (possibility of favorable outcome) as of March 31, 2018 are income taxes payable of 56,108 million yen and deferred tax of 61,784 million yen.

(2) Unrecognized Deferred Tax Assets

Deductible temporary differences, unused tax losses (detail by expiry) and unused tax credits (detail by expiry) for which deferred tax assets are not recognized in the consolidated statement of financial position are as follows:

(Millions of Yen)

	As of March 31, 2017	As of March 31, 2018
Deductible temporary differences	103,123	102,413
Unused tax losses		
Within 1 year	1,572	4,958
Over 1 year within 5 years	8,401	4,906
Over 5 years	51,563	62,486
Total	61,538	72,351
Unused tax credits		
Within 1 year	-	-
Over 1 year within 5 years	-	-
Over 5 years	2,244	2,959
Total	2,244	2,959

(3) Unrecognized Deferred Tax Liabilities

The total temporary differences associated with equity investments in subsidiaries and associates for which deferred tax liabilities are not recognized are 96,495 million yen and 93,475 million yen at March 31, 2017 and 2018, respectively. When the Group can control the timing of the reversal of the temporary differences and it is not probable that the temporary differences will be reversed in the foreseeable future, deferred tax liabilities are not recognized.

(4) Income Taxes Recognized through Profit or Loss

Details of income taxes recognized through profit or loss are as follows:

(Millions of Yen)

	Year ended March 31, 2017	Year ended March 31, 2018
Current period income taxes	35,698	24,384
Deferred income taxes		
Origination and reversal of temporary differences	(6,116)	(2,877)
Change in income tax rate or imposition of new taxation	149	(2,885)
Adjustments and reversals of deferred tax assets	10,577	2,588
Total	4,610	(3,173)
Total income tax expenses	40,309	21,210

Note: Impact of U.S. Tax Reform

The Tax Cuts and Jobs Act was enacted on December 2017 and reduced the U.S. federal corporate tax rate to 21% from 35%, effective from the fiscal year beginning on April 1, 2018. The Group remeasured deferred tax assets and liabilities of U.S. subsidiaries to reflect the effect of this corporate tax rate change. As a result, income taxes decreased by 2,885 million yen for the year ended March 31, 2018. In addition, since the corporate tax rate applicable to the year ended March 31, 2018 was reduced to 31.55% from 35%, income taxes decreased by 1,014 million yen.

(5) Income Taxes Related to Items in Other Comprehensive Income

Details of income taxes recognized through other comprehensive income are as follows:

(Millions of Yen)

	Year ended March 31, 2017			Year ended March 31, 2018		
	Before tax effect	Tax effect	After tax effect	Before tax effect	Tax effect	After tax effect
Financial assets measured at fair value through other comprehensive income	(11,862)	2,495	(9,366)	16,218	(5,530)	10,688
Remeasurements of defined benefit plans	2,739	(899)	1,840	2,215	(599)	1,616
Exchange differences on translation of foreign operations	(7,626)	-	(7,626)	(10,229)	-	(10,229)
Share of other comprehensive income of investments accounted for using the equity method	6	-	6	3	-	3
Total	(16,742)	1,596	(15,146)	8,209	(6,130)	2,078

(6) Reconciliation of Effective Tax Rate

Major sources of differences between the statutory tax rate and effective tax rate are as follows:

	Year ended March 31, 2017	Year ended March 31, 2018
Statutory tax rate	30.7%	30.7%
Permanent non-deductible expenses such as entertainment expenses	2.8%	2.9%
Permanent non-taxable income such as dividends received	(1.3%)	(1.3%)
Changes in unrecognized deferred tax assets	12.1%	3.2%
Effect of different tax rates in foreign jurisdictions	2.9%	1.7%
Tax credit for research and development expenses	(2.0%)	(4.1%)
Adjustment to period-end deferred tax assets due to change in tax rate	0.2%	(4.4%)
Others	0.5%	(2.5%)
Effective tax rate	45.9%	26.2%

Note:

The Company is subject to corporate tax, inhabitant tax, and enterprise tax, which is tax deductible against taxable income for corporate tax purposes when paid. The applicable tax rate based on these taxes is 30.7% for the both years ended March 31, 2017 and 2018. At March 31 2017, the statutory tax rates used for the calculation of deferred tax assets and liabilities are 30.7% for temporary differences expected to reverse from April 1, 2017 to March 31, 2018 and 30.5% for temporary differences expected to reverse after April 1, 2018. At March 31, 2018, the statutory tax rates used for the calculation of deferred tax assets and liabilities is 30.5%. Overseas operations are subject to income taxes of the jurisdictions in which they are located.

17. Trade and Other Payables

Details of “Trade and other payables” in the consolidated statement of financial position are as follows:

(Millions of Yen)

	As of March 31, 2017	As of March 31, 2018
Notes and accounts payable-trade	54,762	68,811
Other accounts payable	65,680	73,946
Others	99,316	83,405
Total	219,759	226,164

18. Bonds and Borrowings, and Other Financial Liabilities

(1) Breakdown of Bonds and Borrowings

Breakdown of “Bonds and borrowings” in the consolidated statement of financial position is as follows:

a. Current Liabilities

(Millions of Yen)

	As of March 31, 2017	As of March 31, 2018
Unsecured bank loans	-	20,000
Total	-	20,000

b. Non-current Liabilities

(Millions of Yen)

	As of March 31, 2017	As of March 31, 2018
Unsecured corporate bonds	179,543	179,564
Unsecured bank loans	101,000	81,000
Total	280,543	260,564

(2) Breakdown of Other Financial Liabilities

Breakdown of “Other financial liabilities” in the consolidated statement of financial position is as follows:

a. Current Liabilities

(Millions of Yen)

	As of March 31, 2017	As of March 31, 2018
Finance lease obligations	535	516
Total	535	516

b. Non-current Liabilities

(Millions of Yen)

	As of March 31, 2017	As of March 31, 2018
Derivative liabilities	2,098	1,786
Finance lease obligations	1,065	1,021
Others	5,904	5,347
Total	9,069	8,155

(3) Terms of Bonds

Terms of bonds are as follows:

(Millions of Yen)

Company name	Name of bond	Date of issuance	As of March 31, 2017	As of March 31, 2018	Interest rate	Maturity date
Daiichi Sankyo Company Limited	2 nd Unsecured corporate bonds	June 24, 2009	40,000	40,000	1.78%	June 24, 2019
Daiichi Sankyo Company Limited	3 rd Unsecured corporate bonds	September 18, 2013	20,000	20,000	0.55%	September 18, 2020
Daiichi Sankyo Company Limited	4 th Unsecured corporate bonds	September 19, 2013	20,000	20,000	0.85%	September 15, 2023
Daiichi Sankyo Company Limited	5 th Unsecured corporate bonds	July 25, 2016	75,000	75,000	0.81%	July 25, 2036
Daiichi Sankyo Company Limited	6 th Unsecured corporate bonds	July 25, 2016	25,000	25,000	1.20%	July 25, 2046
Total	-	-	180,000	180,000	-	-

(4) Terms of Borrowings

Terms of borrowings are as follows:

(Millions of Yen)

Category	As of March 31, 2017	As of March 31, 2018	Average interest rate	Repayment period
Current portion of long-term borrowings	-	20,000	0.00%	-
Long-term borrowings	101,000	81,000	0.01%	Year 2020 to 2023
Total	101,000	101,000	-	-

Note:

Average interest rate is calculated using the ending balance of the borrowings and the interest rates as of March 31, 2018.

19. Provisions

(1) Movement in provisions

Details of the movement in “Provisions” in the consolidated statement of financial position by class of provision are as follows:

Year ended March 31, 2017

(Millions of Yen)

	Sales returns	Sales rebates and deductions	Restructuring	Loss on litigation	Others	Total
Balance as of April 1, 2016	5,767	8,659	20,543	-	5,651	40,623
Increase during the period	12,422	12,198	13,336	-	3,279	41,237
Utilized	(5,573)	(8,241)	(5,539)	-	(2,966)	(22,321)
Reversed unused	-	-	(1,704)	-	(776)	(2,481)
Interest cost due to unwinding of discount	-	-	593	-	2	596
Exchange differences	230	(236)	(478)	-	(158)	(643)
Other increases and decreases	-	-	678	-	(114)	563
Balance as of March 31, 2017	12,847	12,380	27,429	-	4,917	57,574
Current liabilities	12,847	12,380	13,261	-	2,734	41,223
Non-current liabilities	-	-	14,168	-	2,182	16,350
Total	12,847	12,380	27,429	-	4,917	57,574

Year ended March 31, 2018

(Millions of Yen)

	Sales returns	Sales rebates and deductions	Restructuring	Loss on litigation	Others	Total
Balance as of April 1, 2017	12,847	12,380	27,429	-	4,917	57,574
Increase during the period	14,713	8,306	4,544	39,763	3,285	70,613
Utilized	(12,732)	(12,983)	(12,552)	-	(3,753)	(42,021)
Reversed unused	-	-	(1,770)	-	(978)	(2,748)
Interest cost due to unwinding of discount	-	-	626	-	3	630
Exchange differences	(626)	526	444	(1,719)	82	(1,292)
Other increases and decreases	-	-	-	-	11	11
Balance as of March 31, 2018	14,202	8,229	18,722	38,044	3,568	82,767
Current liabilities	14,202	8,229	10,180	-	1,402	34,015
Non-current liabilities	-	-	8,541	38,044	2,166	48,752
Total	14,202	8,229	18,722	38,044	3,568	82,767

(2) Summary of Provisions and Expected Timing of Economic Benefits Outflow

Provisions are calculated based on management's best estimate of the future outflows of economic benefits as of the reporting dates. Due to uncertainty in the underlying assumptions, it is possible that actual results may differ and, as a result, significant adjustments may be required in future periods.

The summary of provisions recorded by the Group and the periods in which the outflow of economic benefits is expected to occur are as set out below. There were no significant asset retirement obligations at March 31, 2017 and 2018.

a. Sales Returns

Provisions for sales returns are recorded by the Company and some consolidated subsidiaries at the amount of estimated loss of sales profit and costs of disposal. These payments are expected to be made mainly within one year.

b. Sales Rebates and Deductions

Provisions for sales rebates and deductions are recorded by the Company and some consolidated subsidiaries based on historical experience to make such payments. These payments are expected to be made mainly within one year.

c. Restructuring

Provisions for restructuring are recognized at the estimated amount of losses for planned restructurings mainly in relation to reduction of the number of employees in Japan, North America and Europe. Provisions for restructuring are recognized when the Group has a detailed formal plan and has raised a valid expectation in those affected that it is certain that the Group will carry out the restructuring by starting to implement the plan or announcing its main features to those affected by it.

The timing of payments will be affected by the progress of the future restructuring of business operations.

d. Loss on litigation

Provisions for loss on litigation are recorded in relation to expected payments related to a lawsuit.

The timing of payments will be affected by the progress of the settlement procedures.

Most amount of payments is expected to be reimbursed by insurance coverage. As of March 31, 2018, the amount of the expected reimbursement from insurance of 37,369 million yen is included in "Other financial assets" (non-current).

20. Employee Benefits

The Company and its domestic subsidiaries mainly adopt the Group's joint defined benefit corporate pension plan and defined contribution plan.

Under the joint defined benefit corporate pension plan, upon retirement, employees enrolled in the plan for longer than a specified vesting period can elect to receive either a pension or lump-sum payment, and employees not fulfilling the vesting period requirement can receive a lump sum payment. In either case the benefits are based on 80% of points accumulated by the time of retirement. This pension plan is operated by a corporate pension fund independent of the Group, and the Group contributes to the plan the amount calculated based on the monthly points assigned for each participant. The fund is to be operated using the contributed amounts to ensure stable benefits to participants. In addition, the Company has established a retirement benefit trust for the joint defined benefit corporate pension plan and contributed marketable securities owned by the Company as trust assets.

Under the defined contribution plan, the Group contributes to a respective employee's individual account in the amount of the monetary value of monthly points, based on 20% of the accumulated points an employee accumulates to retirement, and does not owe a legal or constructive obligation to contribute more than this amount.

The Group may also pay additional, discretionary retirement lump-sum benefits, in addition to the employee benefits plans described above.

Certain overseas components have defined benefit and defined contribution plans.

(1) Present Value of Defined Benefit Obligations

Changes in present value of the defined benefit obligations are as follows:

(Millions of Yen)			
	Plans in Japan	Overseas plans	Total
Balance as of April 1, 2016	136,778	16,928	153,707
Current service cost	5,391	430	5,821
Interest cost	955	316	1,272
Benefits paid	(3,938)	(753)	(4,692)
Employee contributions	-	184	184
Remeasurement – Actuarial losses/(gains) due to changes in demographic assumptions	675	(279)	395
Remeasurement – Actuarial losses/(gains) due to changes in financial assumptions	(2,173)	897	(1,276)
Curtailed and settlement	-	(860)	(860)
Exchange differences	-	(1,050)	(1,050)
Other increases and decreases	-	0	0
Balance as of March 31, 2017	137,688	15,814	153,503
Current service cost	5,266	384	5,650
Interest cost	1,099	313	1,413
Benefits paid	(4,847)	(898)	(5,746)
Employee contributions	-	195	195
Remeasurement – Actuarial losses/(gains) due to changes in demographic assumptions	329	(362)	(32)
Remeasurement – Actuarial losses/(gains) due to changes in financial assumptions	5,014	(443)	4,571
Past service cost	-	(25)	(25)
Exchange differences	-	1,113	1,113
Other increases and decreases	-	2	2
Balance as of March 31, 2018	144,550	16,094	160,645

Note:

Expenses related to employee benefits are reported in Note 25 “Major Expenses by Nature.”

(2) Fair Value of Plan Assets

Changes in fair value of plan assets are as follows:

(Millions of Yen)

	Plans in Japan	Overseas plans	Total
Balance as of April 1, 2016	126,705	13,225	139,931
Interest income	886	259	1,146
Benefits paid	(3,929)	(393)	(4,322)
Employer contributions	4,243	300	4,543
Employee contributions	-	184	184
Remeasurement – Return on plan assets	1,651	277	1,928
Exchange differences	-	(842)	(842)
Balance as of March 31, 2017	129,558	13,011	142,570
Interest income	1,036	264	1,300
Benefits paid	(4,819)	(623)	(5,442)
Employer contributions	4,875	405	5,280
Employee contributions	-	195	195
Remeasurement – Return on plan assets	7,154	2	7,156
Exchange differences	-	938	938
Balance as of March 31, 2018	137,805	14,194	151,999

Note:

The Group expects to contribute 5,328 million yen to defined benefit pension plans for the year ending March 31, 2019.

(3) Fair Value of Plan Assets by Class

Breakdown of fair value of the plan assets by class is as follows:

(Millions of Yen)

	Plans in Japan			
	With quoted prices in active markets		No quoted prices in active markets	
	As of March 31, 2017	As of March 31, 2018	As of March 31, 2017	As of March 31, 2018
Equity securities	47,024	52,045	-	-
Bonds	49,858	47,758	-	-
Real estate	-	-	3,194	3,329
Life insurance general accounts	-	-	18,457	19,213
Others	746	5,210	10,277	10,247
Total	97,628	105,013	31,929	32,791

(Millions of Yen)

	Overseas plans			
	With quoted prices in active markets		No quoted prices in active markets	
	As of March 31, 2017	As of March 31, 2018	As of March 31, 2017	As of March 31, 2018
Equity securities	1,431	1,490	-	-
Bonds	514	551	-	-
Others	1,823	2,164	9,242	9,988
Total	3,769	4,206	9,242	9,988

(4) Asset Ceiling

Changes in the effect of asset ceiling are as follows:

(Millions of Yen)

	Plans in Japan	Overseas plans	Total
Balance as of April 1, 2016	-	-	-
Remeasurement – Effects of limitation to net plan assets due to asset ceiling	-	70	70
Exchange differences	-	0	0
Balance as of March 31, 2017	-	70	70
Remeasurement – Effects of limitation to net plan assets due to asset ceiling	-	402	402
Exchange differences	-	9	9
Balance as of March 31, 2018	-	482	482

(5) Breakdown of Post-employment Benefit Liabilities

Breakdown of “Post-employment benefit liabilities” in the consolidated statement of financial position is as follows:

As of March 31, 2017

(Millions of Yen)

	Plans in Japan	Overseas plans	Total
Present value of defined benefit obligations	137,688	15,814	153,503
Fair value of plan assets	(129,558)	(13,011)	(142,570)
Funding deficit	8,129	2,803	10,932
Impact of asset ceiling	-	70	70
Post-employment benefit assets	141	-	141
Others	232	4	236
Post-employment benefit liabilities	8,503	2,878	11,381

As of March 31, 2018

(Millions of Yen)

	Plans in Japan	Overseas plans	Total
Present value of defined benefit obligations	144,550	16,094	160,645
Fair value of plan assets	(137,805)	(14,194)	(151,999)
Funding deficit	6,745	1,900	8,646
Impact of asset ceiling	-	482	482
Post-employment benefit assets	1,175	7	1,182
Others	231	5	236
Post-employment benefit liabilities	8,152	2,395	10,547

(6) Significant Assumptions and Other Information for Defined Benefit Plans

a. Significant actuarial assumptions

Significant actuarial assumptions are as follows:

	As of March 31, 2017	As of March 31, 2018
Discount rate		
Plans in Japan	0.8%	0.7%
Overseas plans	0.6%~10.9%	0.9%~11.5%

b. Sensitivity Analysis

Effect of a 1% change in actuarial assumptions on the defined benefit obligations is as follows:

(Millions of Yen)

	As of March 31, 2017	As of March 31, 2018
Discount rate		
Effect on defined benefit obligations of 1% increase	(21,898)	(22,035)
Effect on defined benefit obligations of 1% decrease	26,933	26,742

c. Sensitivity Analysis Method, Assumptions and Limitations

The results of the sensitivity analysis show how a 1% increase or decrease in the discount rate would lead to a decrease or increase in the defined benefit obligations as of the reporting date. The effect of the notional discount rate is calculated as an approximation provided by the logarithmic interpolation method, which reflects a conceptual average discount period, based on the notional balances of the defined benefit obligations provided by multiple discount rates.

d. Investment Policy and Management of Plan Assets

The Group manages the plan assets to secure necessary mid-to long-term returns and to build adequate high quality plan assets within acceptable risk levels, in order to ensure future payments of pension benefits and lump-sum payments.

A target rate of return is set using the result of Asset-liability management (“ALM”) analysis, aiming to maintain sound funding of pension financing into the future. Each individual asset is targeted to earn a rate of return exceeding the market rate for each investment category. In aggregate, a target rate of return is set aiming to exceed the combined market rate which is correlated to an investment portfolio for the market in each investment category.

To meet the target returns, the Group defines and pursues strategic asset allocation, which is designed to continue maximizing returns in the future (“the strategic asset mix”) with consideration of expected returns, standard deviations or risks and correlation of each of the investments. The strategic asset mix is determined through the assessment process, including the ALM analysis and the fund’s maturation assessment, from medium-term and long-term perspectives. The strategic asset mix is reviewed every three years, or as needed when there is a significant change in the investment environment.

e. Funding Policy and Rules Affecting Future Contributions

In relation to the joint defined benefit corporate pension plan adopted in Japan, the Group’s funds revise the amounts of contributions every five years to ensure balanced finances for future periods. The funds also revise the amounts of contributions in the event that the balance of the fund reserve falls below the amount of the liability reserve following adjustment by the amount of deficit eligible for carry-forward as of the fund’s reporting date.

The Company and its domestic subsidiaries, which have adopted the joint corporate pension fund, are required to make additional required contributions when the amount of the fund reserve as of the year-end falls below the minimum base amount. They are also required to make a contribution necessary to cover the cost associated with the payments of benefits for the fiscal year in case the reserve is expected to be depleted by the year-end.

f. Maturity Analysis of Defined Benefit Obligations

The weighted average duration of the defined benefit obligations are 16.1 years and 15.0 years as of March 31, 2017 and 2018, respectively.

(7) Defined Contribution Plans

Expenses related to defined contribution plans, which are mainly employer contributions were 13,827 million yen and 14,502 million yen for the years ended March 31, 2017 and 2018, respectively.

21. Government Grants

Amounts of government grants which are recognized as deferred revenue and recorded in “Trade and other payables” and “Other non-current liabilities” in the consolidated statement of financial position are as follows:

(Millions of Yen)

	As of March 31, 2017	As of March 31, 2018
Trade and other payables	2,103	2,044
Other non-current liabilities	13,361	11,400

Note:

Government grants were received mainly to acquire property, plant and equipment related to development and production facilities for influenza vaccine. There are no unfulfilled conditions and other contingencies attached to the government grants presented above.

22. Capital and Other Components of Equity

(1) Share Capital and Capital Surplus

The number of authorized shares and details of fully paid issued shares are as follows:

a. Number of Authorized Shares

(Thousands of shares)

	Number of ordinary shares
April 1, 2016	2,800,000
March 31, 2017	2,800,000
March 31, 2018	2,800,000

b. Details of Fully Paid Issued Shares

	Number of issued shares (Thousands of shares)	Share Capital (Millions of Yen)	Capital surplus (Millions of Yen)
April 1, 2016	709,011	50,000	103,927
March 31, 2017	709,011	50,000	103,750
March 31, 2018	709,011	50,000	94,633

Note:

The shares issued by the Company are ordinary shares with no par value which have no restrictions on any rights.

(2) Treasury Shares

The number and amount of treasury shares are as follows:

	Number of treasury shares (Thousands of shares)	Amount (Millions of Yen)
April 1, 2016	25,618	64,155
March 31, 2017	45,783	113,952
March 31, 2018	61,343	163,531

Notes:

- All treasury shares are owned by the Company.
- The Company operates stock option plans and uses its treasury shares to settle the rights under these plans. Details of the stock option plans are presented in Note 28 “Share-based payments.”
- The Company operates restricted share-based remuneration plans and uses its treasury shares to settle the rights under these plans.

(3) Other Components of Equity

a. Subscription Rights to Shares

The Company operates stock option plans and subscription rights to shares are issued in accordance with the Japanese Companies Act.

b. Exchange Differences on Translation of Foreign Operations

Exchange differences arise from translating financial statements of foreign operations.

c. Cash flow Hedges

Effective portion of the cumulative net change in fair value of cash flow hedging instruments.

d. Financial Assets Measured at Fair Value through Other Comprehensive Income

Changes in fair value of financial assets measured at fair value through other comprehensive income.

e. Remeasurements of Defined Benefit Plans

Remeasurements of defined benefit liabilities and assets.

23. Dividends

(1) Amount of Dividends Paid

Year ended March 31, 2017

Resolution	Class of shares	Total amount of dividends (Millions of Yen)	Dividend per share (Yen)	Record date	Effective date
General shareholders' meeting held on June 20, 2016	Ordinary shares	20,501	30.0	March 31, 2016	June 21, 2016
Board of Directors' meeting held on October 31, 2016	Ordinary shares	23,378	35.0	September 30, 2016	December 1, 2016

Year ended March 31, 2018

Resolution	Class of shares	Total amount of dividends (Millions of Yen)	Dividend per share (Yen)	Record date	Effective date
General shareholders' meeting held on June 19, 2017	Ordinary shares	23,212	35.0	March 31, 2017	June 20, 2017
Board of Directors' meeting held on October 31, 2017	Ordinary shares	23,217	35.0	September 30, 2017	December 1, 2017

(2) Dividends with Record Date in the Year but whose Effective Date is in the Following Year

Year ended March 31, 2017

Resolution	Class of shares	Total amount of dividends (Millions of Yen)	Dividend per share (Yen)	Record date	Effective date
General shareholders' meeting held on June 19, 2017	Ordinary shares	23,212	35.0	March 31, 2017	June 20, 2017

Year ended March 31, 2018

Resolution	Class of shares	Total amount of dividends (Millions of Yen)	Dividend per share (Yen)	Record date	Effective date
General shareholders' meeting held on June 18, 2018	Ordinary shares	22,668	35.0	March 31, 2018	June 19, 2018

24. Revenue

Breakdown of "Revenue" in the consolidated statement of profit or loss are as follows:

(Millions of Yen)

	Year ended March 31, 2017	Year ended March 31, 2018
Sales of finished goods and merchandise	912,311	929,248
Others	42,813	30,946
Total	955,124	960,195

25. Major Expenses by Nature

Information related to major expenses by nature is as follows:

(Millions of Yen)

	Year ended March 31, 2017	Year ended March 31, 2018
Advertisement and promotional expenses	91,714	96,374
Salaries and bonuses	156,052	162,449
Statutory benefits	16,727	17,632
Post-employment benefits	21,090	21,091
Other employee benefit expenses	3,024	4,612
Rent and leases	16,507	15,391
Depreciation and amortization	47,373	46,680
Gain on sale of property, plant and equipment	(867)	(8,288)
Loss on disposal of property, plant and equipment	1,317	3,163
Impairment loss	26,459	36,672
Restructuring costs	12,937	4,496

26. Financial Income and Financial Expenses

(1) Financial Income

Breakdown of “Financial income” is as follows:

(Millions of Yen)

	Year ended March 31, 2017	Year ended March 31, 2018
Interest income		
Financial assets measured at amortized cost:		
Bank deposits	737	852
Loans receivable	33	26
Bonds	871	1,335
Others	13	0
Financial assets measured at fair value through profit or loss	355	252
Dividend income		
Financial assets measured at fair value through other comprehensive income:		
Dividend income from financial assets held at the end of the year	1,894	1,817
Dividend income from financial assets derecognized during the year	227	223
Financial assets measured at fair value through profit or loss	0	237
Gain from change in fair value and realized gain		
Financial assets and liabilities measured at fair value through profit or loss		
Derivatives	798	312
Others	1,387	1,875
Net foreign exchange gains	-	1,664
Others	88	44
Total	6,406	8,642

(2) Financial Expenses

Breakdown of “Financial expenses” is as follows:

(Millions of Yen)

	Year ended March 31, 2017	Year ended March 31, 2018
Interest expenses		
Financial liabilities measured at amortized cost:		
Borrowings	61	100
Bonds	1,612	1,896
Finance lease liabilities	45	32
Others	4	20
Others	598	633
Loss on change in fair value and realized loss		
Financial assets and liabilities measured at fair value through profit or loss:		
Derivatives	474	439
Others	170	760
Net foreign exchange losses	1,254	-
Others	3,488	339
Total	7,710	4,223

Note:

”Others” in “Financial expenses” for the year ended March 31, 2017 is mainly the change in the fair value of contingent consideration related to the acquisition of Ambit Biosciences Corporation.

27. Earnings Per Share

(1) Basis for calculation of Basic Earnings per Share

	Year ended March 31, 2017	Year ended March 31, 2018
a. Profit Attributable to owners of the Company		
Profit attributable to owners of the Company (Millions of Yen)	53,466	60,282
Profit not attributable to owners of the Company (Millions of Yen)	-	-
Profit used to calculate basic earnings per share (Millions of Yen)	53,466	60,282
b. Weighted-average Number of Ordinary Shares		
Weighted-average number of ordinary shares (basic) (Thousands of shares)	671,422	660,161
c. Basic Earnings per Share		
Basic earnings per share (Yen)	79.63	91.31

(2) Basis for calculation of Diluted Earnings per Share

	Year ended March 31, 2017	Year ended March 31, 2018
a. Diluted Profit Attributable to owners of the Company		
Profit used to calculate basic earnings per share (Millions of Yen)	53,466	60,282
Adjustments to profit (Millions of Yen)	-	-
Profit used to calculate diluted earnings per share (Millions of Yen)	53,466	60,282
b. Weighted-average Number of Diluted Ordinary Shares		
Weighted-average number of ordinary shares (basic) (Thousands of shares)	671,422	660,161
Potential effect of issue of subscription right to shares (Thousands of shares)	1,610	1,550
Weighted-average number of ordinary shares (diluted) (Thousands of shares)	673,033	661,712
c. Diluted Earnings per Share		
Diluted earnings per share (Yen)	79.44	91.10

28. Share-based Payments

The Company operates stock option plans and has implemented restricted share-based remuneration plans in the year ended March 31, 2018. In addition, some subsidiaries issue share appreciation rights as cash-settled share-based payments.

(1) Details of Restricted Share-based Remuneration Plans, the Number of Shares Granted During the Year, and their Fair Values

Details of restricted share-based remuneration plans, the number of shares granted during the year, and their fair values are as follows:

	Year ended March 31, 2018
Grant date	July 18, 2017
Granted (Shares)	123,324
Fair value (Yen)	2,456.5

Notes:

1. Restricted shares are granted to members of the Company's Board of Directors and Corporate Officers, excluding external Board members ("holders of subscription rights to restricted shares").
2. The transfer restriction period is four years, and the restriction is cancelled when the transfer restriction period expires on the condition that holders of subscription rights to restricted shares continuously served as either a member of the Company's Board of Directors or as a Corporate Officer who does not concurrently serve as a member of the Company's Board of Directors throughout the restriction period.
3. The Company forms a restricted share allotment agreement with the holders of subscription rights to restricted shares which prohibits them from transferring, creating any security interest on, or otherwise disposing of the Company's ordinary shares that have been received by allotment under the agreement for a specified period, The agreement also include the Company's right to acquire the said ordinary shares without contribution in the case where specified events happen.

(2) Details of Stock Option Plans and Unexercised Balances as of March 31, 2018

Details of stock option plans and unexercised balances as of March 31, 2018 are as follows:

	Number of stock options		Grant date	Exercise period of granted options
	Granted (Shares)	Unexercised (Shares)		
1 st issuance subscription rights to shares (as stock options)	101,900	35,900	February 15, 2008	From February 16, 2008 to February 15, 2038
2 nd issuance subscription rights to shares (as stock options)	172,200	69,000	November 17, 2008	From November 18, 2008 to November 17, 2038
3 rd issuance subscription rights to shares (as stock options)	230,800	136,700	August 17, 2009	From August 18, 2009 to August 17, 2039
4 th issuance subscription rights to shares (as stock options)	237,100	209,800	August 19, 2010	From August 20, 2010 to August 19, 2040
5 th issuance subscription rights to shares (as stock options)	232,800	206,200	July 12, 2011	From July 13, 2011 to July 12, 2041
6 th issuance subscription rights to shares (as stock options)	295,400	262,800	July 9, 2012	From July 10, 2012 to July 9, 2042
7 th issuance subscription rights to shares (as stock options)	192,800	192,800	July 8, 2013	From July 9, 2013 to July 8, 2043
8 th issuance subscription rights to shares (as stock options)	145,000	145,000	July 8, 2014	From July 9, 2014 to July 8, 2044
9 th issuance subscription rights to shares (as stock options)	118,700	118,700	July 7, 2015	From July 8, 2015 to July 7, 2045
10 th issuance subscription rights to shares (as stock options)	135,200	135,200	July 5, 2016	From July 6, 2016 to July 5, 2046
Total	1,861,900	1,512,100	-	-

Notes:

1. The stock option plans are equity-settled.
2. Stock options are granted to members of the Company's Board of Directors and Corporate Officers, excluding external Board members.

3. Persons to whom stock options are granted (“holders of subscription rights to shares”) may exercise their subscription rights to shares until the end of the fiscal year that ends within 10 years from the day following their resignation from the office as a Member of the Board of Directors or as a Corporate Officer of the Company which they held when the subscription rights to shares were granted. If the holders of subscription rights to shares concurrently serve as a Member of the Board of Directors and Corporate Officer, the day of resignation from the office is the day they retire from the office as a Member of the Board of Directors, regardless of whether they continued to hold the position of a Corporate Officer. If the holders of subscription rights to shares served as a Corporate Officer when the subscription rights to shares were granted and if they took office as a Member of the Board of Directors upon their resignation as a Corporate Officer, the day when they resigned from the office is the day when they resign from the office as a Member of the Board of Directors, and not the day when they retire as a Corporate Officer.
4. There are no vesting conditions for the stock options.
5. Number of stock options represents the number of ordinary shares that would be issued upon exercise of the stock options.

(3) Movement in the Number of Stock Options and the Exercise Prices

Movement in the number of stock options and the exercise prices are as follows:

	Year ended March 31, 2017		Year ended March 31, 2018	
	Number of stock options (Shares)	Weighted average exercise price (Yen)	Number of stock options (Shares)	Weighted average exercise price (Yen)
Unexercised balance at the beginning of the year	1,526,300	1	1,569,600	1
Granted	135,200	1	-	-
Exercised	(91,900)	1	(57,500)	1
Expired	-	-	-	-
Unexercised balance at the end of the year	1,569,600	1	1,512,100	1
Options outstanding	1,569,600	1	1,512,100	1
Range of exercise prices	1 Yen		1 Yen	
Weighted average remaining contractual life	25.18 years		24.26 years	

Notes:

1. Number of stock options represents the number of ordinary shares that would be issued upon exercise of the stock options.
2. Weighted average share price at the exercise date for the stock options which were exercised during the period is 2,596 yen and 3,055 yen for the years ended March 31, 2017 and 2018, respectively.

(4) Fair Value Measurement of Stock Options Granted During the Period

No stock options were granted in the year ended March 31, 2018.

The fair value of stock options granted during the year ended March 31, 2017 is measured based on the Black-Scholes option pricing model.

Basic inputs and assumptions used for the Black-Scholes option pricing model are primarily as follows:

	Year ended March 31, 2017
	10 th issuance subscription rights to shares (as stock options)
Fair value	1,960 Yen
Share price at grant date	2,569.5 Yen
Exercise price	1 Yen
Expected volatility	30.7% (note 1)
Remaining life of options (note 2)	10 years
Expected dividends (note 3)	70 Yen / share
Risk-free interest rate (note 4)	(0.3%)

Notes:

1. Calculated based on historical share price in the period from July 6, 2006 to July 5, 2016.
2. Estimated based on the assumption that the stock options will be exercised in the middle of the exercise period since historical data is not sufficiently available to support a reasonable estimate.
3. Based on historical dividends in the preceding 12 months.
4. Interest rate of government bonds for the period corresponding to the expected remaining life.

(5) Share-based Payment Expenses

Breakdown of share-based payment expenses is as follows:

(Millions of Yen)

	Year ended March 31, 2017	Year ended March 31, 2018
Equity-settled	264	272
Cash-settled	3,615	5,740
Total	3,880	6,012

Notes:

1. Equity-settled share-based payment transactions in the year ended March 31, 2017 are the stock option plans.
2. Equity-settled share-based payment transactions in the year ended March 31, 2018 are the restricted share-based remuneration plans.
3. Cash-settled share-based payment transaction consists of Stock Appreciation Right ("SAR") and Restricted Stock Unit ("RSU"), which some consolidated subsidiaries grant to specific employees.
For a SAR, the Company pays cash based on the difference between the stock price on the grant date and the exercise date, and rights are vested three years after the grant date and are exercisable within the following seven years.
RSU rights are vested three years after the grant date, and the Company pays cash based on the stock price as of the date the rights are vested and applicable dividends.
4. Liabilities arising from cash-settled share-based payment transactions are 7,061 million yen and 8,585 million yen as of March 31, 2017 and 2018, respectively.

29. Financial Instruments

(1) Risk Management

The Group is exposed to credit risks, foreign currency exchange risks, interest rates risks, market price fluctuation risks and liquidity risks arising from operating and financing activities. The Group uses derivative instruments only to hedge these risks, and the Group's policy is not to enter into speculative derivative transactions. Each group company's finance department executes and manages derivative transactions. A derivative transaction management policy is established, which states limitation of authorities and transaction amounts. Derivative transactions are executed and managed in accordance with this policy and are reported to the Board of Directors.

a. Credit Risk

Trade receivables, such as notes receivables and accounts receivable- trade, are exposed to the credit risk of the customers. The Company's Sales Administration Department periodically monitors the condition of major customers and controls outstanding balances and due dates for each individual customer in accordance with the credit management policy to identify collectability issues at an early stage in an effort to mitigate the credit risks. Consolidated subsidiaries also perform the same controls in accordance with the Company's credit management policy.

The Group is exposed to credit risks of financial institutions holding deposits and issuers of bonds. The Group executes transactions only with highly rated counterparties within credit limits, which are determined for each of the counterparties in accordance with the fund management policy to minimize concentration risk.

Derivative transactions are exposed to credit risks of counterparties. The Group executes transactions only with highly rated financial institutions in order to mitigate the counterparties' credit risk.

The maximum exposure to credit risks at the reporting date is the carrying value of instruments stated in the consolidated statement of financial position. The Group does not hold securities as collateral.

i) Ageing Analysis of Financial Assets that are Past Due at the End of Reporting Period and Not Impaired

Ageing Analysis of financial assets that are past due at the end of reporting period and not impaired is as follows:
(Millions of Yen)

	As of March 31, 2017	As of March 31, 2018
Past due by 1-30 days	286	316
Past due by 31-60 days	116	68
Past due by 61-90 days	16	27
Past due by 91-120 days	39	68
Past due by more than 120 days	236	340

Note: There are no assets which are held as collateral or other compensation for the above balances.

ii) Movement in Allowance for Doubtful Accounts

The Group considers collectability of receivables based on credit conditions of the counterparties and recognizes an allowance for doubtful accounts. The movement of allowance for doubtful accounts is as follows:

(Millions of Yen)

	Year ended March 31, 2017	Year ended March 31, 2018
Balance at the beginning of the year	382	481
Increase during the period	210	91
Utilized	(38)	(19)
Reversed unused	(69)	(90)
Others (including exchange differences)	(4)	(7)
Balance at the end of the year	481	454

b. Foreign Currency Exchange Risks

Trade receivables, trade payables denominated in foreign currencies, which arise from the Company's global operations, are exposed to foreign currency exchange risks.

i) Exposure to Foreign Currency Exchange Risks

Net exposure to foreign currency exchange risks is as set out below. The amount does not include exposure to foreign currency exchange risks that is hedged by derivatives.

	As of March 31, 2017	As of March 31, 2018
U.S. dollar (Thousands of U.S. dollar)	(295,668)	(132,190)
Euro (Thousands of Euro)	(4,393)	8,836

ii) Foreign Exchange Sensitivity Analysis

The impact of a 1% appreciation in the Yen against the U.S. dollar and Euro on profit before tax for the financial instruments held by the Group at each year-end is as set out below. This analysis is based on the assumption that other factors remain constant. The exposure to fluctuations of all foreign currencies other than U.S. dollar and Euro is not significant.

(Millions of Yen)

	As of March 31, 2017	As of March 31, 2018
U.S. dollar	331	140
Euro	5	(11)

c. Interest Rate Risks

Borrowings with variable interest rates are exposed to interest rate risks. The Group uses interest rates swaps to hedge interest rate risks.

i) Exposure to Interest Rate Risk

Exposure to the interest rate risk is as set out below. The amount does not include the exposure to interest rate risks that are hedged by derivatives.

(Millions of Yen)

	As of March 31, 2017	As of March 31, 2018
Borrowings with variable interest rates	40,000	40,000

ii) Interest Rate Sensitivity Analysis

The impact of a 1% increase in the interest rates on profit before tax for the financial instruments held by the Group at each year-end is set out below. This analysis is based on the assumptions that other factors remain constant.

(Millions of Yen)

	As of March 31, 2017	As of March 31, 2018
Impact on profit before tax	(400)	(400)

d. Market Price Fluctuation Risk

The Group holds bonds and shares issued by companies including business partners which are exposed to market price fluctuation risks. The Group regularly monitors the fair value of the instruments and financial condition of the issuers (business partners) and continuously reconsiders composition of holdings of securities to manage market price fluctuation risks.

Some subsidiaries use cash-settled share-based payment transactions based on the Company's shares, which are exposed to share price fluctuation risks.

e. Liquidity Risk

Liquidity risk is the risk that the Group is not able to meet the obligations associated with its financial liabilities as they become due. The Group continuously monitors cash flow planning and actual results to manage liquidity risks. The Group also has commitment line contracts with financial institutions and maintains credit lines which are useable to manage liquidity risks.

Outstanding balances by due date of major financial liabilities are as follows:

As of March 31, 2017

(Millions of Yen)

	Carrying amount	Contractual cash flows	Within 1 year	Over 1 year within 2 years	Over 2 years within 3 years	Over 3 years Within 4 years	Over 4 years Within 5 years	Over 5 years
Unsecured Corporate bonds	179,543	203,956	1,896	1,896	41,541	21,131	1,076	136,412
Unsecured bank loans	101,000	101,177	31	20,031	30	20,029	20,025	41,028
Derivative liabilities	2,098	2,415	431	431	431	431	370	318
Total	282,642	307,549	2,360	22,360	42,004	41,593	21,472	177,759

As of March 31, 2018

(Millions of Yen)

	Carrying amount	Contractual cash flows	Within 1 year	Over 1 year Within 2 years	Over 2 years Within 3 years	Over 3 years Within 4 years	Over 4 years Within 5 years	Over 5 years
Unsecured Corporate bonds	179,564	202,059	1,896	41,541	21,131	1,076	1,076	135,335
Unsecured bank loans	101,000	101,044	20,008	8	20,008	20,008	20,008	21,004
Derivative liabilities	1,786	2,123	462	462	462	396	251	87
Total	282,351	305,227	22,367	42,012	41,602	21,481	21,335	156,427

(2) Fair Value of Financial Instruments

a. Fair value and carrying amount of financial instruments

Comparison between fair value and carrying amount of financial instruments is as follows:

(Millions of Yen)

	As of March 31, 2017		As of March 31, 2018	
	Carrying amount	Fair value	Carrying amount	Fair value
Financial liabilities				
Bonds	179,543	179,720	179,564	182,657
Borrowings	101,000	101,034	101,000	101,030

b. Measurement of Fair Values

Measurement methods of fair values are as follows:

i) Other Financial Assets and Other Financial Liabilities

For financial instruments traded in an active market, the fair value is determined by reference to the quoted market price. When there is no active market, the fair value of the financial instruments is measured by using appropriate valuation methods. The fair value of derivatives is measured by reference to quotes obtained from financial institutions which are contractual counterparties.

ii) Bonds

The fair value of bonds is determined by reference to the quoted market price. The bonds are categorized as Level 1 in the fair value hierarchy.

iii) Borrowings

The fair value of borrowings with variable interest rates reflects the market rate in the short-term and therefore approximates the carrying value. Fair value of borrowings with fixed interest rates is discounted using an expected market interest rate based on the assumption that the total principal amount is newly borrowed on the same terms and conditions. The borrowings are categorized as level 3 in the fair value hierarchy.

Fair value of all other financial assets and liabilities approximates carrying amounts.

(3) Fair Value Hierarchy

a. Fair Value Hierarchy

The fair value hierarchy of financial instruments is summarized as follows:

Level 1: Fair value measured at quoted prices in active markets for identical assets or liabilities

Level 2: Fair value measured using inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly

Level 3: Fair value measured by appropriate valuation methods using inputs that are not based on observable market data

Transfers of financial instruments among these levels are recognized at the end of each quarter of the year.

As of March 31, 2017

(Millions of Yen)

	Level 1	Level 2	Level 3	Total
Financial assets				
Financial assets measured at fair value through profit or loss:				
Bonds	727	9,832	-	10,560
Others	7,458	136,719	-	144,178
Financial assets measured at fair value through other comprehensive income:				
Equity securities	105,537	-	14,468	120,005
Others	-	-	2,650	2,650
Total	113,724	146,551	17,118	277,394
Financial liabilities				
Financial liabilities measured at fair value through profit or loss:				
Derivative liabilities	-	2,098	-	2,098
Contingent consideration	-	-	6,066	6,066
Total	-	2,098	6,066	8,165

Notes:

1. There were no transfers of financial instruments between the levels.
2. "Others" categorized as level 2 under "Financial assets measured at fair value through profit or loss" includes 136,244 million yen of foreign-currency bank deposits embedding forward foreign exchange contracts.
3. "Contingent consideration" under "Financial liabilities measured at fair value through profit or loss" is included in "Other non-current liabilities" in the consolidated statement of financial position.

As of March 31, 2018

(Millions of Yen)

	Level 1	Level 2	Level 3	Total
Financial assets				
Financial assets measured at fair value through profit or loss:				
Bonds	-	1,811	-	1,811
Others	8,837	133,110	-	141,948
Financial assets measured at fair value through other comprehensive income:				
Equity securities	103,637	-	18,842	122,479
Others	-	-	47	47
Total	112,475	134,922	18,889	266,287
Financial liabilities				
Financial liabilities measured at fair value through profit or loss:				
Derivative liabilities	-	1,786	-	1,786
Contingent consideration	-	-	5,760	5,760
Total	-	1,786	5,760	7,547

Notes:

1. There were no transfers of financial instruments between the levels.
2. "Others" categorized as level 2 under "Financial assets measured at fair value through profit or loss" includes 132,633 million yen of foreign-currency bank deposits embedding forward foreign exchange contracts.
3. "Contingent consideration" under "Financial liabilities measured at fair value through profit or loss" is included in "Other non-current liabilities" in the consolidated statement of financial position.

b. Reconciliation of Level 3 Fair Values

The following table shows reconciliation from the opening balances to the ending balances for Level 3 fair values.

Year ended March 31, 2017

(Millions of Yen)

	Financial assets measured at fair value through other comprehensive income	Financial assets measured at fair value through profit or loss	Total
Balance at the beginning of the year	18,365	-	18,365
Gain (Loss)	(2,184)	-	(2,184)
Purchase	937	-	937
Sale and settlement	(0)	-	(0)
Balance at the end of the year	17,118	-	17,118

Notes:

1. The fair value of unlisted shares is categorized as Level 3 and measured at fair value using comparable peer company analysis and other valuation models, such as the net asset method. Since unobservable inputs, such as EBITDA, are used in these valuation models, the fair value of these shares is categorized as Level 3. To measure fair value, EBITDA ratio in the range of 3.4~32.7 is used based on the corresponding comparable peer companies. When the EBITDA ratio increases, the fair value also increases.
2. The above table does not include contingent consideration arising from business combinations, which is included in Note 7 "Business Combination."

Year ended March 31, 2018

(Millions of Yen)

	Financial assets measured at fair value through other comprehensive income	Financial assets measured at fair value through profit or loss	Total
Balance at the beginning of the year	17,118	-	17,118
Gain (Loss)	3,715	-	3,715
Purchase	322	-	322
Sale and settlement	(2,267)	-	(2,267)
Balance at the end of the year	18,889	-	18,889

Notes:

- The fair value of unlisted shares is categorized as Level 3 and measured at fair value using comparable peer company analysis and other valuation models, such as the net asset method. Since unobservable inputs, such as EBITDA, are used in these valuation models, the fair value of these shares is categorized as Level 3. To measure fair value, EBITDA ratio in the range of 5.6~29.5 is used based on the corresponding comparable peer companies. When the EBITDA ratio increases, the fair value also increases.
- The above table does not include contingent consideration arising from business combinations, which is included in Note 7 "Business Combination."

(4) Derivatives and Hedge Accounting

a. Cash Flow Hedges

The Group uses forward foreign exchange contracts to hedge movements of cash flows associated with future business transactions denominated in foreign currencies. When criteria for hedge accounting are met, they are designated as cash flow hedges. The effective portion of changes in fair value related to hedging instruments is recognized in other comprehensive income, and the ineffective portion of changes in fair value is recognized in profit or loss. The accumulated amount recognized in equity through other comprehensive income is reclassified to profit or loss when the hedged transaction affects profit or loss. In the year ended March 31, 2017 and 2018, there is no reclassification to profit or loss.

b. Derivatives Not Designated as Hedging Instruments

The Group uses derivatives when economically reasonable even if the hedging arrangement does not meet the criteria for hedge accounting.

The Group uses the following derivatives which are not designated as hedging instruments:

- Forward foreign exchange contracts to hedge foreign currency exchange risk; and
- Interest rates swaps to hedge fluctuations of variable interest rates for borrowings.

The Group does not hold derivatives for speculative purposes.

c. Fair Values of Derivatives

Fair values of derivatives are as follows:

(Millions of Yen)

	As of March 31, 2017	As of March 31, 2018
Derivative liabilities		
Interest related	2,098	1,786
Total	2,098	1,786

(5) Capital Management

The Group recognizes the necessity of securing liquidity and fund raising capacity to enable flexible investments to enhance shareholder returns as well as to achieve sustainable growth.

Therefore, the Group monitors movement in mid-to-long term liquidity, credit ratings which demonstrate the soundness of financial condition, and the appropriate capital structure.

In addition, one of the Group's objectives is to achieve ROE of more than 8% in 2020 through implementing business-operations strategies and investments for future growth, as set out in the fourth mid-term business plan for the period between 2016 and 2020.

The major indicators the Group employs for capital management are as follows:

(Millions of Yen)

	As of March 31, 2017	As of March 31, 2018
Cash plus marketable securities (note 1)	798,223	786,456
Bonds and borrowings	280,543	280,564
Net cash	517,679	505,891
Total shareholder return ratio (note 2)	180.7%	159.1%

Notes:

1. "Cash plus marketable securities" includes cash and cash equivalents, and securities with original maturities of more than three months.
2. "Total shareholder return ratio" is calculated based on (Dividends plus total acquisition costs of treasury shares) / Profit attributable to owners of the Company.

There are no significant capital adequacy requirements applicable to the Group.

30. Lease Transactions

The Group has lease contracts as lessee for certain real estate and machinery. Certain lease arrangements include renewal options and rent escalation clauses. There are no limitations arising from the lease contracts.

(1) Finance Leases

Future lease payments for finance leases are as follows:

(Millions of Yen)

	Future minimum lease payments		Present value of future minimum lease payments	
	As of March 31, 2017	As of March 31, 2018	As of March 31, 2017	As of March 31, 2018
Within 1 year	557	542	535	516
Over 1 year within 5 years	1,049	1,023	1,029	993
Over 5 years	35	27	35	27
Total	1,641	1,593	1,600	1,537
Less - Interest	(41)	(56)	-	-
Present value of future minimum lease payments	1,600	1,537	1,600	1,537

(2) Operating Leases

Future minimum lease payments for non-cancellable operating leases are as follows:

(Millions of Yen)

	As of March 31, 2017	As of March 31, 2018
Within 1 year	4,470	4,938
Over 1 year within 5 years	15,058	13,199
Over 5 years	15,526	13,135
Total	35,055	31,273

31. Other Comprehensive Income

Reclassification adjustments related to “Other comprehensive income” are as follows:

(Millions of Yen)

	Year ended March 31, 2017	Year ended March 31, 2018
Other comprehensive income that are or may be reclassified to profit or loss		
Exchange differences on translation of foreign operations		
Change for the year	(7,619)	(10,230)
Reclassification adjustments	(7)	1
Subtotal	(7,626)	(10,229)
Share of other comprehensive income of investments accounted for using the equity method		
Change for the year	6	3
Reclassification adjustments	-	-
Subtotal	6	3
Other comprehensive income, before adjustments for tax effects	(7,620)	(10,225)
Tax effects	-	-
Total	(7,620)	(10,225)

32. Changes in Liabilities Arising from Financing Activities

Changes in liabilities arising from financing activities are as follows:

(Millions of Yen)

	Borrowings	Bonds	Finance lease liabilities	Total
Balance as of April 1, 2017	101,000	179,543	1,600	282,144
Changes from financing cash flows	-	-	(1,196)	(1,196)
Non-cash changes				
Acquisitions	-	-	1,206	1,206
Exchange differences	-	-	(73)	(73)
Others	-	21	-	21
Balance as of March 31, 2018	101,000	179,564	1,537	282,101

33. Related Parties

(1) Transactions with Related Parties

Transactions with related parties are on the same terms as the normal course of business. There were no material transactions with related parties for the years ended March 31, 2017 and 2018.

(2) Remuneration of Key Management Personnel

(Millions of Yen)

	Year ended March 31, 2017	Year ended March 31, 2018
Remuneration and bonuses	568	633
Stock options	114	-
Restricted share-based remuneration	-	91
Total	682	724

34. Commitments

Total contractual amounts of commitments for acquisition of assets after the end of each year are as follows:

(Millions of Yen)

	As of March 31, 2017	As of March 31, 2018
Property, plant and equipment	5,798	41,078
Intangible assets	192,019	76,389
Total	197,817	117,468

Note:

The commitments for intangible assets mainly relate to the acquisitions of sales licenses for technology introduction, and represent the milestone payments based on the achievement of milestones associated with the medical research and development objectives. The amounts presented above represent the maximum payments if all milestones are achieved and may differ from the actual amounts paid.

35. Contingent Liabilities

(1) Loan Guarantees

The Company provides loan guarantees in relation to its associate's and employees' borrowings from financial institutions as shown below. In the event that the associate and employees are unable to repay their debt, the Company will need to bear the unpaid amounts.

(Millions of Yen)

	As of March 31, 2017	As of March 31, 2018
Japan Vaccine Co., Ltd. (operating capital)	1,000	1,000
Employees (housing and other loans)	743	580

(2) Others

The Company concluded an agreement with Sun Pharmaceutical Industries Ltd. ("Sun Pharma") in April 2014 under which Sun Pharma acquired Ranbaxy Laboratories Ltd. ("Ranbaxy") in exchange for receipt by Daiichi Sankyo of shares in Sun Pharma on March 24, 2015 ("the closing date").

Based on the agreement with Sun Pharma, the Company could be required to indemnify Sun Pharma for 63.5% of penalties and damages arising from quality issues of Ranbaxy prior to the closing date, which are paid to U.S. federal or state governmental authorities by Sun Pharma or Ranbaxy, with a maximum cap amount of 325 million U.S. dollar. This obligation lasts for seven years from the closing date. In April 2015, Daiichi Sankyo sold all of the acquired Sun Pharma shares, while the aforementioned agreement remains in effect.

Although the Company could incur damages as a result of the above-mentioned contingent liabilities, it is not considered possible at present to reasonably estimate the monetary amount of any such damages.

The Group estimates the possible outflow of economic benefits due to settlement of contingent liabilities by using all available inputs at the reporting date. Except for the items noted above, there are no contingent liabilities that could have a significant impact on the Group's operations in future periods.

No provision is recognized for the above contingent liabilities since the possibility of outflow of economic benefits is considered remote, or the provision cannot be reasonably estimated.

36. Major Consolidated Subsidiaries and Associates

Major consolidated subsidiaries and associates as of March 31, 2018 are as follows:

Consolidated Subsidiaries

Company	Location	Function	Percentage of voting rights (%)
Daiichi Sankyo Espha Co., Ltd.	Chuo-ku, Tokyo, Japan	Pharmaceuticals	100.0
Daiichi Sankyo Healthcare Co., Ltd.	Chuo-ku, Tokyo, Japan	Pharmaceuticals	100.0
Daiichi Sankyo Propharma Co., Ltd.	Chuo-ku, Tokyo, Japan	Pharmaceuticals	100.0
Daiichi Sankyo Chemical Pharma Co., Ltd.	Chuo-ku, Tokyo, Japan	Pharmaceuticals	100.0
Asubio Pharma Co.,Ltd.	Chuo-ku, Kobe, Japan	Pharmaceuticals	100.0
Daiichi Sankyo RD Novare Co.,Ltd.	Edogawa-ku, Tokyo, Japan	Pharmaceuticals	100.0
Daiichi Sankyo Business Associe Co., Ltd.	Chuo-ku, Tokyo, Japan	Other	100.0
Kitasato Daiichi Sankyo Vaccine Co., Ltd. (note 1)	Kitamoto, Saitama, Japan	Pharmaceuticals	100.0
Japan Vaccine Distribution Co., Ltd. (note 2)	Chiyoda-ku, Tokyo, Japan	Pharmaceuticals	50.0
Daiichi Sankyo U.S. Holdings, Inc.	New Jersey, United States	Pharmaceuticals	100.0
Daiichi Sankyo Inc.	New Jersey, United States	Pharmaceuticals	100.0
Plexxikon Inc.	California, United States	Pharmaceuticals	100.0
Luitpold Pharmaceutical, Inc.	New York, United States	Pharmaceuticals	100.0
Ambit Biosciences Corp.	California, United States	Pharmaceuticals	100.0
Daiichi Sankyo Europe GmbH	Munich, Germany	Pharmaceuticals	100.0
Daiichi Sankyo France SAS	Ryu El Malmaison, France	Pharmaceuticals	100.0
Daiichi Sankyo Deutschland GmbH	Munich, Germany	Pharmaceuticals	100.0
Daiichi Sankyo Italia S.p.A.	Rome, Italy	Pharmaceuticals	100.0
Daiichi Sankyo España S.A.	Madrid, Spain	Pharmaceuticals	100.0
Daiichi Sankyo UK Ltd.	Buckinghamshire, United Kingdom	Pharmaceuticals	100.0
Daiichi Sankyo (China) Holdings Co., Ltd.	Shanghai, China	Pharmaceuticals	100.0
Daiichi Sankyo Pharmaceutical (Beijing) Co., Ltd.	Beijing, China	Pharmaceuticals	100.0
Daiichi Sankyo Pharmaceutical (Shanghai) Co., Ltd.	Shanghai, China	Pharmaceuticals	100.0
Daiichi Sankyo Taiwan Ltd.	Taipei, Taiwan	Pharmaceuticals	100.0
Daiichi Sankyo Korea Co., Ltd.	Seoul, South Korea	Pharmaceuticals	100.0
Daiichi Sankyo Brasil Farmacêutica LTDA.	Sao Paulo, Brazil	Pharmaceuticals	100.0

Associates accounted for using the equity method

Company	Location	Function	Percentage of voting rights (%)
Japan Vaccine Co., Ltd.	Chiyoda-ku, Tokyo, Japan	Pharmaceuticals	50.0
Hitachi Pharma Evolutions Ltd.	Chiyoda-ku, Tokyo, Japan	Other	49.0

Notes:

- In order to strengthen the financial base of Kitasato Daiichi Sankyo Vaccine Co., Ltd., the Company underwrote all of the shares issued by Kitasato Daiichi Sankyo Vaccine in September 2017. In addition, the Company acquired all of the shares of Kitasato Daiichi Sankyo Vaccine in November 2017. As a result, the Company has 100% of the voting rights as of March 31, 2018 (80% as of March 31, 2017).
- The Group includes Japan Vaccine Distribution Co., Ltd. as its consolidated subsidiary because the Group has substantial control over Japan Vaccine Distribution Co., Ltd. despite the fact that the Group does not own more than 50% of the voting interest.

37. Subsequent Events
Not applicable



Independent Auditor's Report

To the Board of Directors of Daiichi Sankyo Co., Ltd.:

We have audited the accompanying consolidated financial statements of Daiichi Sankyo Co., Ltd. and its subsidiaries, which comprise the consolidated statement of financial position as at March 31, 2018, and the consolidated statement of profit or loss, consolidated statement of comprehensive income, consolidated statement of changes in equity and consolidated statement of cash flows for the year then ended, and notes to the consolidated financial statements.

Management's Responsibility for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with International Financial Reporting Standards, and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these consolidated financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in Japan. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on our judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, we consider internal control relevant to the entity's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, while the objective of the financial statement audit is not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of Daiichi Sankyo Co., Ltd. and its subsidiaries as at March 31, 2018, and their financial performance and cash flows for the year then ended in accordance with International Financial Reporting Standards.

Other Matter

We have no interest in the Company which should be disclosed pursuant to the provisions of the Certified Public Accountants Law of Japan.

KPMG AZSA LLC

KPMG AZSA LLC

June 18, 2018

Tokyo, Japan